



NRG ONCOLOGY

2026 SUMMER MEETING

DENVER





PROGRAM BOOK

NRG ONCOLOGY 2026 SUMMER MEETING

DENVER, COLORADO

#NRG2026

Table of Contents

3 Welcome Message
4 NRG Mission Statement
5 Continuing Education Information
6 Approved CME Session Credit List
7 Social Media and WiFi Information
8 Meeting App Information
9 Venue Map
11 Meeting Agenda

SESSIONS/SPECIAL EVENTS

15 The NRG Podcast
16 Winter Symposium - *"Ovarian Cancer Prevention is Our Duty, When We Fail: Recurrence, Mitigation, and Treatment Strategies for Ovarian Cancer"*
18 PSC Nurse/CRA Continuing Education Session
20 PSC Discuss With Us Live
22 Advanced Practice Providers (APP) Symposium
25 Pathology Committee
27 PSC Roundtable Sessions
30 Early Career & Investigator Development Committee Investigator Development Roundtable Sessions
33 Translational Science Committee
35 NCORP Town Hall
37 General Session
39 FORTE Workshop: Protocol Compliance Best Practices
41 Scientific Session
44 Communications & Digital Engagement Workshop

WORKSHOP AGENDAS (CME/NON-CME)

46 Adaptive RT Working Group
48 Brain Tumor General Committee
49 Canadian Subcommittee
50 Cancer Prevention & Control Committee
51 Cervical/Vulvar Cancer Subcommittee
57 Developmental Therapeutics Committee
59 Gastrointestinal Cancer General Committee
61 Genitourinary Cancer General Committee
63 Health Care Access (HCA) Committee
64 HCA Older Adult SIG
65 HCA Research Concept Development SIG
66 Imaging Committee
67 Immunotherapy Subcommittee
68 Medical Oncology Committee
69 Medical Physics Subcommittee
71 Ovarian Cancer Subcommittee
75 Particle Therapy Working Group
77 Patient-Centered Outcomes (PCOR) Committee
78 Radiation Oncology Committee
79 Radiation Oncology GYN Working Group
80 Rare Tumor Subcommittee
82 Theranostics Subcommittee
84 Translational Science Brain Tumor Working Group
85 Translational Science GU Cancer Working Group
86 Translational Science GYN Cancer Working Group
87 Translational Science H&N Cancer Working Group
88 Translational Science Lung Cancer Working Group
89 Uterine Corpus Cancer Subcommittee

INSTITUTIONAL ACCRUAL

91 Member Accrual

ACKNOWELDGEMENTS

97 Congratulations Travel Awardees
98 Sponsors/Exhibitors
101 AbbVie Sponsor Advertisement
102 Corcept Therapeutics Sponsor Advertisement
103 Gilead - NRG Supporters Program Advertisement
104 NRG Supporters Program Partners
105 Independent Medical Education Grant Support
107 Future Meeting Dates and Locations



Welcome to Denver

We are delighted to welcome you to Denver, Colorado for our 2026 Summer Meeting! This conference brings together leaders in oncology research, clinical care, and trial development, creating a dynamic forum for investigators, clinicians, nurses, research professionals, patient advocates, and industry partners to collaborate and drive progress in improving cancer outcomes.

There are many special sessions you may wish to attend at this year's NRG Meeting. On Thursday, July 16, 2026, we will host our Summer Symposium titled "Ovarian Cancer Prevention is Our Duty-When We Fail: Recurrence Mitigation and Treatment Strategies for Ovarian Cancer" from 8:00am-12:15pm MT. This symposium will address challenging topics in ovarian cancer such as early detection and prevention, new therapeutics for patients with advanced ovarian cancer such as antibody-drug conjugates, and treatment of platinum resistant and refractory ovarian cancer.

Our NRG Scientific Session, which typically showcases recent practice-changing results that have stemmed from NRG research, will be held on Friday, July 17, 2026, from 3:00-4:30pm MT. This year, it will also include a focus on NRG's early career investigators and their research.

Our second Advanced Practice Providers (APPs) Symposium will be held at this meeting on Thursday, July 16, 2026, from 12:00-1:30pm MT. This symposium is designed to bridge the gap between APPs and NCI sponsored research.

We invite everyone to join us for the NRG Reception on Friday evening from 6:00 to 8:00pm MT. This is a wonderful opportunity to network with colleagues, connect with old and new friends, and enjoy refreshments.

If this is your first NRG meeting, we encourage you to actively participate and share your perspectives. Our sessions are designed to spark meaningful discussion, and your engagement plays an important role in their success. By contributing, you will help to move forward the NRG's current and new initiatives. We encourage you to explore the complete agenda in the Program Book to choose the sessions that interest you.



Quynh-Thu Le, MD
NRG Oncology Group Chair



Robert Mannel, MD
NRG Oncology Group Chair



Norman Wolmark, MD
NRG Oncology Group Chair

NRG ONCOLOGY

Advancing Research. Improving Lives.™

NRG Oncology's
Mission Statement

NRG Oncology seeks to improve the lives of patients with cancer by conducting practice-changing multi-institutional clinical and translational research with emphases on sex-specific malignancies including gynecologic, breast, and prostate cancers and on localized or locally advanced cancers of all types.

For the Educational Objectives, we list the following:

- Inform the participants of the current state of clinical and basic oncologic research, particularly, but not exclusively as it relates to clinical trials.
- Provide participants with peer review critiques of progress (or lack of it) with the objective of self-improvement.
- Provide an opportunity to learn research administration and financial management in a cooperative group setting.
- Provide a forum for experts from diverse fields to improve research practices and patient management.

CONTINUING EDUCATION

CME Credit and PSC Contact Hours (Formerly CEUs)



ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Joint Providership of The GOG Foundation, Inc. and NRG Oncology.

The GOG Foundation, Inc. is accredited by the ACCME to provide Continuing Education for physicians.

AMA PRA CATEGORY 1 CREDITS™

The GOG Foundation, Inc. designates this live activity for a maximum of **14.25 AMA PRA Category 1 Credits™**.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO CLAIM CME CREDITS

1. **Scan QR Code** to Complete evaluation

Overall Meeting Evaluation:
https://s.pointerpro.com/nrgjuly2026

Evaluation will not be active until the conclusion of the NRG Meeting (July 21st)

2. **Select Sessions** and **Enter Credits** being claimed

3. **Click Submit** and your CME certificate will automatically be emailed to you.

SYMPOSIUM

Symposium Evaluation links will be emailed to all registered attendees.

DISCLOSURE DECLARATION

In compliance with ACCME regulations, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation. Please see the complete disclosure list included with this program.

OFF-LABEL STATEMENT

Some of the presentations and discussions in this session may include the off-label use of products/ devices.

CONTACT HOURS (FORMERLY CEUS)

PSC Evaluation Links will be emailed to all registered attendees.

EVALUATIONS MUST BE SUBMITTED BY: AUGUST 7, 2026

QUESTIONS

CMEs: If you have issues accessing your certificate or questions about CME please contact: cmeinfo@gog.org

PSC Contact Hours: For questions about Contact Hours (formerly CEUs) please contact: meeting-reg@NRGOncology.org

GOG FOUNDATION®
Transforming the standard of care

CME Credit Listing

The following sessions/workshops have been estimated to receive CME credits for the Summer 2026 Semiannual Meeting July 16 - 18, 2026.
Maximum credits up to ***14.25*** *AMA PRA Category 1 Credits™*

Upon review of each session, the GOG Foundation reserves the right to reduce the number of credits based on compliance of ACCME guidelines.

Thursday, July 16, 2026		Credits	Credits Claimed
12:00 pm – 1:30 pm	Advance Practice Practitioners Symposium	1.50	
12:30 pm – 2:30 pm	Developmental Therapeutics Committee	1.00	
2:30 pm – 4:30 pm	Rare Tumor Subcommittee	2.00	

Friday, July 17, 2026		Credits	Credits Claimed
8:00 am – 10:00 am	Cervical / Vulvar Cancer Committee	2.00	
10:00 am – 11:30 am	NCORP Town Hall	.75	
10:00 am – 12:00 pm	Uterine Corpus Cancer Subcommittee	2.00	
1:00 pm – 3:00 pm	Ovarian Cancer Subcommittee Workshop	1.25	
3:00 pm – 4:30 pm	Scientific Session	1.50	

Saturday, July 18, 2026		Credits	Credits Claimed
7:30 am – 9:00 pm	Genitourinary Cancer Workshop	1.50	
11:00 am – 12:30 pm	Gastrointestinal Cancer Committee Workshop	1.50	

NRG2026

at your finger tips

FOLLOW

Twitter / X
@NRGOnc

Facebook
@NRG Oncology

Instagram
@NRGOnc

LinkedIn
@NRG Oncology

YouTube
@NRGOnc

Bluesky
@nrgonc.bsky.social

Use the hashtag **#NRG2026** to join the conversation.

CONNECT TO WIFI

Network Login: nrgmeeting
Passcode: n1r2g345

CHECK OUT OUR MEETING WEBPAGES

The NRG2026 main agenda, session flyers, attendee information, and more are posted on our NRG2026 webpages located at: www.nrgoncology.org/2026-Summer-Mtg

Continue to check these pages after NRG2026 ends as we will update this section with any available presentation slides and recordings.



NRG2026
Meeting App

1. Go to the Apple Store or Google Store
2. Download the CVENT Events App
3. Select CVENT EVENTS
4. Search for Event = NRG
5. Select: "NRG Oncology Summer 2026 Meeting"
6. Event ID = NRG ONCS26
   (Please note there is a space after NRG)




Once you have downloaded the NRG Oncology Summer Meeting app, you will be asked to enter your first name, last name, and the email that you used to register for the event.




You'll receive a 6-digit verification code to your email. Enter the code on the screen. Tap the arrow.

Opt in to receive push notifications so you don't miss any important information!

Venue Map


TOWER
MEZZANINE LEVEL
DENVER
SPRUCE
CENTURY
GOLD
SILVER
COLORADO
ASPEN
SECOND LEVEL
SOUTH CONVENTION LOBBY
PLAZA
GRAND BALLROOM
SKYBRIDGE
GUESTROOMS
TOWER A
TOWER B
TOWER C
TOWER D
WINDOWS
STREET LEVEL
15TH STREET ENTRANCE
DIRECTOR'S ROW E-J
FITNESS CENTER
16TH STREET COMMONS CAFE
SHERATON CLUB
16TH STREET COMMONS COFFEE BAR
FRONT DESK
ZOUP
MAIN ENTRANCE
COURT PL.
PARLUR
YARDHOUSE
BEZEL
16TH STREET MALL

Venue Map


TERRACE LEVEL
COLUMBINE
CAPITOL
TERRACE
BILTMORE
BEVERLY
MAJESTIC LEVEL
VAIL
MAJESTIC BALLROOM
SAVOY
TOWER
FEDEX
CONCOURSE LEVEL
C
F
B
PLAZA BALLROOM
E
A
D
17
16
15
14
GOVERNORS SQUARE
PLAZA REGISTRATION OFFICE
9
10
8
11
7
12
6
PLAZA EXHIBIT
PLAZA COURT
1
2
3
4
5
GARAGE LEVEL
PLAZA

NRG ONCOLOGY

Advancing Research, Improving Lives.™

NRG ONCOLOGY SEMIANNUAL MEETING PRELIMINARY AGENDA

Sheraton Denver Downtown Hotel Denver, CO

July 16-18, 2026

Thursday, July 9, 2026		
7:00 pm - 8:30 pm ET 5:00 pm – 6:30 pm MT	Publications Committee *(Closed)*	Virtual Only
Friday, July 10, 2026		
11:00 am - 12:00 pm ET 9:00 am – 10:00 am MT	Local Regional Breast Cancer Working Group	Virtual Only
1:00 pm - 2:00 pm ET 11:00 am – 12:00 pm MT	Head & Neck Skin Working Group	Virtual Only
1:00 pm - 3:30 pm ET 11:00 am - 1:30 pm MT	Translational Science Lung Cancer Working Group	Virtual Only
2:00 pm - 3:00 pm ET 12:00 pm - 1:00 pm MT	Breast Cancer Rare Tumor Working Group	Virtual Only
Monday, July 13, 2026		
11:00 am - 1:00 pm ET 9:00 am - 11:00 am MT	Medical Oncology Committee	Virtual Only
1:00 pm - 2:00 pm ET 11:00 am - 12:00 pm MT	Communications & Digital Engagement Workshop (*formerly Social Media*)	Virtual Only
1:00 pm – 2:00 pm ET 11:00 am – 12:00 pm MT	Translational Science Breast Cancer Working Group	Virtual Only
1:00 pm - 2:00 pm ET 11:00 am - 12:00 pm MT	VA/MTF Subcommittee	Virtual Only
1:30 pm - 2:30 pm ET 11:30 am - 12:30 pm MT	Imaging Committee	Virtual Only
2:30 pm - 4:00 pm ET 12:30 pm - 2:00 pm MT	Medical Physics Subcommittee	Virtual Only
Tuesday, July 14, 2026		
11:00 am - 12:30 pm ET 9:00 am - 10:30 am MT	Pharmacy Subcommittee	Virtual Only
1:00 pm - 2:00 pm ET 11:00 am - 12:00 pm MT	QA Subcommittee *(Closed)*	Virtual Only
3:00 pm - 5:00 pm ET 1:00 pm - 3:00 pm MT	Immunotherapy Subcommittee	Virtual Only
5:00 pm - 6:00 pm ET 3:00 pm - 4:00 pm MT	Head & Neck Patient-Reported Outcomes/Cost Effectiveness Working Group	Virtual Only

Thursday, July 16, 2026		
6:30 am – 7:30 am MT	Protocol Support Committee Nurse/CRA Breakfast	PLAZA |CONCOURSE LEVEL| Plaza AB
6:30 am – 8:00 am MT	Symposium Breakfast	PLAZA |CONCOURSE LEVEL| Plaza DE
7:00 am – 6:00 pm MT	Exhibits	PLAZA |CONCOURSE LEVEL| Plaza Exhibit
7:00 am – 6:00 pm MT	Registration/Information Desk	PLAZA |CONCOURSE LEVEL| Plaza Registration
2:00 pm – 4:00 pm MT	General Coffee Break	PLAZA |CONCOURSE LEVEL| Plaza Registration
9:30 am - 2:00 pm ET 7:30 am - 12:00 pm MT	Protocol Support Committee (PSC) Nurse/CRA Continuing Education Session *(Webinar)*	PLAZA |CONCOURSE LEVEL| Plaza AB
8:00 am - 10:00 am MT	Patient Advocate Committee *(Closed)*	PLAZA |CONCOURSE LEVEL| Governor's Square 15
10:00 am - 2:15 pm ET 8:00 am - 12:15 pm MT	Summer 2026 Symposium: Ovarian Cancer Prevention is Our Duty-When We Fail: Recurrence Mitigation and Treatment Strategies for Ovarian Cancer *(Webinar)*	PLAZA |CONCOURSE LEVEL| Plaza DE
12:00 pm - 1:00 pm ET 10:00 am - 11:00 am MT	International Members Subcommittee *(Webinar)*	PLAZA |CONCOURSE LEVEL| Governor's Square 15
10:15 am – 11:45 am MT	Health Care Access (HCA) Committee	PLAZA |CONCOURSE LEVEL| Governor's Square 14

1:00 pm - 2:00 pm ET 11:00 am - 12:00 pm MT	Canadian Members Subcommittee *(Webinar)*	PLAZA |CONCOURSE LEVEL| Governor's Square 15
12:00 pm – 1:15 pm MT	PSC Nurse/CRA Lunch & Learn - Discuss With Us *(Pre-Registration Required)*	TOWER |SECOND FLOOR LEVEL| Grand I
12:00 pm – 1:30 pm MT	Advanced Practice Provider (APP) Symposium	PLAZA |CONCOURSE LEVEL| Governor's Square 14
12:15 pm – 1:45 pm MT	Membership Committee *(Closed)*	PLAZA |CONCOURSE LEVEL| Governor's Square 10
12:30 pm – 2:30 pm MT	Developmental Therapeutics Committee	PLAZA |CONCOURSE LEVEL| Plaza CF
1:00 pm – 3:00 pm MT	Pathology Committee	PLAZA |CONCOURSE LEVEL| Governor's Square 17
1:30 pm – 4:45 pm MT	PSC Nurse/CRA Continuing Education Roundtables	TOWER |SECOND FLOOR LEVEL| Grand I
1:45 pm – 3:15 pm MT	Cancer Prevention and Control (CPC) Committee	TOWER |ALPINE LEVEL| Alpine Ballroom
2:00 pm – 3:00 pm MT	Adaptive Radiation Therapy Working Group	TOWER |ALPINE LEVEL| Vail
2:00 pm – 3:00 pm MT	Head & Neck Rare Tumor Working Group	TOWER |TERRACE LEVEL| Telluride
2:30 pm – 4:00 pm MT	Investigator & Career Development Committee Roundtable Session	TOWER |SECOND FLOOR LEVEL| Windows
2:30 pm – 4:30 pm MT	Rare Tumor Subcommittee	PLAZA |CONCOURSE LEVEL| Plaza CF
3:00 pm – 4:00 pm MT	Head & Neck Previously Untreated Locoregionally Advance Working Group	TOWER |MEZZANINE LEVEL| Silver
3:00 pm – 4:00 pm MT	Theranostics Subcommittee	PLAZA |CONCOURSE LEVEL| Governor's Square 17
3:00 pm – 4:30 pm MT	Ancillary Projects Committee *(Closed)*	PLAZA |CONCOURSE LEVEL| Governor's Square 10
3:00 pm – 5:00 pm MT	Translational Science Committee	PLAZA |CONCOURSE LEVEL| Plaza AB
3:30 pm – 5:00 pm MT	Patient Centered Outcomes Research (PCOR) Committee	PLAZA |CONCOURSE LEVEL| Governor's Square 14
4:00 pm – 5:00 pm MT	Investigator & Career Development Committee Networking Session	TOWER |SECOND FLOOR LEVEL| Windows
4:30 pm – 5:30 pm MT	Radiation Oncology Gynecologic Working Group	TOWER |MEZZANINE LEVEL| Silver
5:15 pm – 6:30 pm MT	Committee Chair Meeting *(Closed)*	PLAZA |CONCOURSE LEVEL| Governor's Square 12

Friday, July 17, 2026

6:30 am – 8:30 am MT	Continental Breakfast	PLAZA |CONCOURSE LEVEL| Plaza Registration
7:00 am – 5:30 pm MT	Exhibits	PLAZA |CONCOURSE LEVEL| Plaza Exhibit
7:00 am – 5:30 pm MT	Registration/Information Desk	PLAZA |CONCOURSE LEVEL| Plaza Registration
10:00 am – 12:00 pm MT	General Coffee Break	PLAZA |CONCOURSE LEVEL| Plaza Registration
3:00 pm – 5:00 pm MT	General Coffee Break	PLAZA |CONCOURSE LEVEL| Plaza Registration
6:00 am – 7:30 am MT	Endometrial Consortium, Route 66 SPORE, Protocol 210 *(Closed)*	PLAZA |CONCOURSE LEVEL| Governor's Square 16
7:00 am – 8:00 am MT	Voting Members PI Breakfast *(Closed)*	TOWER |SECOND FLOOR LEVEL| Windows
7:30 am – 9:30 am MT	Brain Tumor Core Committee *(Closed)*	TOWER |ALPINE LEVEL| Alpine Ballroom
8:00 am – 10:00 am MT	Cervix/Vulvar Cancer Subcommittee	PLAZA |CONCOURSE LEVEL| Plaza CF
8:00 am – 10:00 am MT	Head & Neck Surgical Working Group	TOWER |SECOND FLOOR LEVEL| Grand II
8:00 am – 10:00 am MT	Radiation Oncology Committee	PLAZA |CONCOURSE LEVEL| Plaza AB
8:00 am – 12:00 pm MT	Breast Cancer Core Committee *(Closed)*	TOWER |SECOND FLOOR LEVEL| Grand I
8:30 am – 9:45 am MT	NCORP Concept Review *(Closed)*	PLAZA |CONCOURSE LEVEL| Governor's Square 11
9:40 am – 10:40 am MT	Neurosurgical Working Group	TOWER |ALPINE LEVEL| Alpine Ballroom
10:00 am – 11:30 am MT	NCORP Townhall	TOWER |SECOND FLOOR LEVEL| Grand II
10:00 am – 12:00 pm MT	Head & Neck Cancer General Committee	PLAZA |CONCOURSE LEVEL| Governor's Square 14
10:00 am – 12:00 pm MT	Uterine Corpus Cancer Subcommittee	PLAZA |CONCOURSE LEVEL| Plaza CF
10:15 am – 11:45 am MT	Particle Therapy Working Group	PLAZA |CONCOURSE LEVEL| Plaza AB
10:50 am – 11:50 am MT	Translational Science Brain Tumor Working Group	TOWER |ALPINE LEVEL| Alpine Ballroom
12:00 pm – 1:00 pm MT	General Session	PLAZA |CONCOURSE LEVEL| Plaza DE
1:00 pm – 2:00 pm MT	HCA Committee Breakout Session: Research Concept Development SIG	PLAZA |CONCOURSE LEVEL| Plaza Court 1
1:00 pm – 3:00 pm MT	Genitourinary Cancer Core Committee (Closed)	PLAZA |CONCOURSE LEVEL| Governor's Square 15
1:00 pm – 3:00 pm MT	Lung Cancer Core Committee (Closed)	PLAZA |CONCOURSE LEVEL| Governor's Square 11
1:00 pm – 3:00 pm MT	Ovarian Cancer Subcommittee	PLAZA |CONCOURSE LEVEL| Plaza CF
1:00 pm – 3:00 pm MT	Sarcoma Subcommittee	PLAZA |CONCOURSE LEVEL| Governor's Square 17
1:15 pm – 2:30 pm MT	FORTE Workshop	PLAZA |CONCOURSE LEVEL| Governor's Square 14

1:00 pm – 3:00 pm MT	Translational Science Head & Neck Cancer Working Group	TOWER |SECOND FLOOR LEVEL| Grand I
1:15 pm – 2:45 pm MT	Brain Tumor Committee General Session	TOWER |ALPINE LEVEL| Alpine Ballroom
1:15 pm – 2:45 pm MT	PSC Education & Training Subcommittee *(Closed)*	PLAZA |CONCOURSE LEVEL| Plaza Court 6
1:15 pm – 2:45 pm MT	PSC Mentorship Subcommittee *(Closed)*	TOWER |SECOND FLOOR LEVEL| Tower Court C
1:15 pm – 2:45 pm MT	PSC Protocol Review Subcommittee *(Closed)*	TOWER |SECOND FLOOR LEVEL| Tower Court A
1:15 pm – 2:45 pm MT	PSC Quality Control & Communication Subcommittee *(Closed)*	TOWER |SECOND FLOOR LEVEL| Tower Court B
2:00 pm – 3:00 pm MT	HCA Committee SIG Leadership Meeting *(Closed)*	PLAZA |CONCOURSE LEVEL| Plaza Court 1
3:00 pm – 4:30 pm MT	Scientific Session	PLAZA |CONCOURSE LEVEL| Plaza DE
3:00 pm – 5:00 pm MT	Head & Neck Cancer Core Committee *(Closed)*	PLAZA |CONCOURSE LEVEL| Governor's Square 12
4:30 pm – 5:30 pm MT	HCA Committee Breakout Session: Older Adult SIG	PLAZA |CONCOURSE LEVEL| Governor's Square 10
4:30 pm – 6:00 pm MT	PSC CTN/CRA Subcommittee Joint Meeting *(Closed)*	PLAZA |CONCOURSE LEVEL| Governor's Square 15
4:30 pm – 6:00 pm MT	Translational Science Genitourinary Cancer Working Group	TOWER |SECOND FLOOR LEVEL| Grand I
6:30 pm - 8:00 pm ET 4:30 pm – 6:00 pm MT	Translational Science GYN Cancer Working Group	Virtual Only
4:30 pm – 6:15 pm MT	Lung Cancer General Committee	PLAZA |CONCOURSE LEVEL| Plaza AB
5:00 pm – 7:00 pm MT	Korean Gynecologic Oncology Group	PLAZA |CONCOURSE LEVEL| Governor's Square 16
6:00 pm – 8:00 pm MT	NRG Oncology Reception	PLAZA |CONCOURSE LEVEL| Plaza Exhibit

Saturday, July 18, 2026

6:30 am – 10:00 am MT	Continental Breakfast	PLAZA |CONCOURSE LEVEL| Plaza Registration
7:00 am – 11:00 am MT	Exhibits	PLAZA |CONCOURSE LEVEL| Plaza Exhibit
7:00 am – 11:00 am MT	Registration/Information Desk	PLAZA |CONCOURSE LEVEL| Plaza Registration
7:00 am – 9:30 am MT	PSC Core Executive Committee Session *(Closed)*	PLAZA |CONCOURSE LEVEL| Plaza Court 2 - 3
7:30 am – 9:00 am MT	Gastrointestinal Colorectal Cancer Core Committee *(Closed)*	PLAZA |CONCOURSE LEVEL| Governor's Square 12
7:30 am – 9:00 am MT	Genitourinary Cancer General Committee	PLAZA |CONCOURSE LEVEL| Plaza DE
7:30 am – 9:00 am MT	Gynecologic Cancer General Committee	PLAZA |CONCOURSE LEVEL| Plaza CF
7:30 am – 9:00 am MT	Protocol Operations Management Committee *(Closed)*	PLAZA |CONCOURSE LEVEL| Governor's Square 9
9:15 am – 10:45 am MT	Gastrointestinal Non-Colorectal Cancer Core Committee *(Closed)*	PLAZA |CONCOURSE LEVEL| Governor's Square 12
11:00 am – 12:30 pm MT	Gastrointestinal Cancer General Committee	PLAZA |CONCOURSE LEVEL| Plaza DE

Friday, July 24, 2026

11:00 am – 2:00 pm ET 9:00 am – 12:00 pm MT	Breast Cancer General Committee	Virtual Only

Monday, July 27, 2026

6:30 pm – 8:00 pm ET 4:30 pm – 6:00 pm MT	Surgical Oncology Committee	Virtual Only

Revised 07/06/2026



NRG ONCOLOGY

Special Events, Sessions, and Workshops

#NRG2026

THE NRG ONCOLOGY PODCAST

Moving the needle in cancer care



with Co-hosts

Stephen Chun, MD
&
Lauren Henke, MD

2025 ACRO
Media Award Recipient

LISTEN ON:

SPOTIFY

APPLE PODCASTS

YOUTUBE

AMAZON MUSIC



NRG Summer 2026 Semiannual Meeting

SUMMER SYMPOSIUM

OVARIAN CANCER PREVENTION IS OUR DUTY, WHEN WE FAIL: RECURRENCE, MITIGATION AND TREATMENT STRATEGIES FOR OVARIAN CANCER

July 16, 2026 | 8:00am -12:15pm MT

Program Chairs: Ursula Matulonis, MD and Joan Walker, MD

PROGRAM DESCRIPTION:
The Summer 2026 Educational Symposium will target and address topics in ovarian cancer that are particularly challenging such as early detection and prevention, incorporating new therapies into treatment of patients with advanced ovarian cancer such as antibody drug conjugates, and treatment of platinum resistant and refractory ovarian cancer.

TARGET AUDIENCE:
This educational activity is directed towards members and non-members including our broad audience of physicians, research staff, new investigators, clinical research associates, basic researchers, medical physics, clinical trial nurses, patient advocates and other health care professionals interested in the treatment of cancer.

LEARNING OBJECTIVES: Following this activity, participants will be better able to:

- Develop a basic knowledge of early detection tests for ovarian cancer and trial results.
- Explain the rationale for opportunistic salpingectomy and its role in ovarian cancer risk reduction.
- Describe the evidence supporting new therapeutic interventions for both newly diagnosed ovarian cancer as well as recurrent cancer.
- Discuss the strategies for treatment of platinum resistant and refractory cancer.

Continuing Education:
This Symposium is approved to earn 4 AMA PRA Category 1 CME Credits.

See Presentation Agenda on next page

SYMPOSIUM AGENDA		
7:00 am – 8:00 am	**Breakfast Buffet**	
8:00 am	Welcome/Opening Remarks	TBD GOG-F EMC Representative
8:05 am	Symposium Introduction	Joan Walker, MD and Ursula Matulonis, MD
8:10 am	**Session 1: Empower to Prevent: Steps to Eradicate Ovarian Cancer**	**Moderator: Joan Walker, MD** Session Introduction
8:10 – 8:25 am	Event Horizon of Population-Level Ovarian Cancer Prevention	Rebecca Stone, MD
8:26 – 8:41 am	BioEngineering the End of Ovarian Cancer	Angie Belcher, PhD
8:42 – 8:57 am	Universally Fast & Familial: The New Standard for Ovarian Cancer Screening	Kari Ring, MD
8:58 – 9:18 am	STIC-ing it to Cancer: Creative Clinical Trial Design and Interactive Panel Discussion	Joan Walker, MD Ronnie Drapkin, MD, PhD Ie-Ming Shih, MD, PhD
9:19 – 9:35 am	**Panel Discussion with Q/A with Audience Response**	**ALL**
9:35 am	**Session 2: Catch the ADC Wave**	**Moderator: Ursula Matulonis, MD** - Session Introduction
9:37 – 9:52 am	Start Early with Smart Bombs: Precision Medicine for First-Line Treatment	Joyce Liu, MD
9:53 – 10:07 am	Precision Payloads to Target Recurrence	Ramez Eskander, MD
10:08 – 10:24 am	Precision without the Punch: Handling ADCs with Care	Brad Corr, MD
10:25 – 10:40 am	**Panel Discussion with Q/A with Audience Response**	**ALL**
10:40 – 11:00 am	**Coffee Break**	
11:00 am	**Session 3: Beyond ADCs: New Treatment Strategies for Ovarian Cancer**	**Moderators: Joan Walker, MD, Ursula Matulonis, MD and Fiona Simpkins, MD, PhD** Session Introduction
11:02 - 11:17 am	Turning Replication Stress into a PROC Lethal Weapon	Fiona Simpkins, MD
11:18 – 11:33 am	Exploiting Chromosomal Instability in PROC with KIF	Cara Mathews, MD
11:34 – 11:49 am	The Platinum Rechallenge Roadmap in Recurrent Ovarian Cancer	Robert Coleman, MD
11:50 – 12:05 pm	LGSOC: The Clamp and What's Next	Gottfried Konecny, MD
12:06 – 12:15 pm	**Panel Discussion with Q/A: The ROC Navigation Plan: Mapping the Best Treatment Route**	**ALL**
12:15 pm	**Closing Remarks**	

Protocol Support Committee

Nurse / Clinical Research Associate Continuing Education Session

Thursday, July 16, 2026
7:30 am - 12:00 pm MT

In-Person & Virtual

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

#NRG2026

PROGRAM FACILITATORS

Cynthia Licavoli, RN, BSN, MHA
Marissa Weiss, MBA
Jacqueline Ludwig, RN, BSN, CCRP

SPEAKERS

Sharon Hartson Stine, MS, BA
NRG Oncology Welcome & Updates

Sara McCarthy, MS, RN
AE/SAE Reporting Updates

Mary Jo Antonelli, MBA, MHA
NRG Oncology Quality Assurance Update

Danielle Enserro, PhD
The Power of Effective Data Management: Bridging the Gap Between Data Collection & Statistical Analysis for Clinical Trial Success

Cynthia Licavoli, RN, BSN, MHA
NRG Oncology Protocol Support Committee

Rachel Albershardt, MS, CRP
Clinical Trials Support Unit (CTSU)

Jeffrey Yap, PhD &
Helosia Soares, MD, PhD
Theranostics 101

Thomas George, MD, FACP, FASCO
Liquid Biopsies for Cancer: Pearls & Pitfalls

Jacqueline Ludwig, RN, BSN, CCRP
Wrap up & Evaluations

This nursing continuing professional development activity was approved by Virginia Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

Session Information

Protocol Support Committee
Nurse/Clinical Research Associate Continuing Education Session: PSC Discuss With Us LIVE
Session Date: Thursday, July 16, 2026 Session Time: 7:30 am MT- 12:00 pm MT

Program Chairs:

PSC Chair: **Cynthia Licavoli RN, BSN, MHA**
PSC Vice Chairs: **Nancy Fusco RN, BSN, CCRP & Marissa Weiss, MBA**
Program Facilitators: **Cynthia Licavoli RN, BSN, MHA, Marissa Weiss, MBA & Jacqueline Ludwig, RN, BSN, CCRP**

Meeting Agenda

Time	Topic	Speaker
7:30 am-7:40 am	Welcome & Introductions	Cynthia Licavoli, RN, BSN, MHA & Jacqueline Ludwig, RN, BSN, CCRP
7:40 am- 7:50 am	NRG Oncology Welcome & Updates	Sharon Hartson Stine, MS, BA
7:50 am- 8:25 am	AE/SAE Reporting Updates	Sara McCartney, MS, RN
8:25 am-8:50 am	NRG Oncology Quality Assurance Update	Mary Jo Antonelli, MBA, MHA
8:50 am- 9:25 am	The Power of Effective Data Management: Bridging the Gap Between Data Collection & Statistical Analysis for Clinical Trial Success	Danielle Enserro, PhD
9:25 am – 9:35 am	Break	
9:35 am- 9:55 am	NRG Oncology Protocol Support Committee	Cynthia Licavoli, RN, BSN, MHA
9:55 am 10:20 am	Clinical Trials Support Unit (CTSU)	Rachel Albershardt, MS, CRP
10:20 am – 11:10 am	Theranostics 101	Jeffrey Yap, PhD & Helosia Soares, MD, PhD
11:10 am- 12:00 pm	Liquid Biopsies for Cancer: Pearls and Pitfalls	Thomas George, MD, FACP, FASCO
12:00 pm- 12:15 pm	Wrap up & Evaluations	Jacqueline Ludwig, RN, BSN, CCRP

Additional Notes:

Session is offered in-person or virtual

This nursing continuing professional development activity was approved by Virginia Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

Protocol Support Committee

Nurse / Clinical Research Associate
Continuing Education Lunch & Learn Session



NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

#NRG2026

LIVE

PSC

DISCUSS WITH US
ENGAGE. EXCHANGE. EVOLVE.

Thursday, July 16, 2026
12:00-1:15 pm MT
In-Person Only

WELCOME

Erin McCaig, RN, BSN

TOPIC

Patient Advocacy: Bridging the Gap Between Researchers & Patients

Lisa Lenrow & Kimberly Williams
NRG Oncology Patient Advocates

This nursing continuing professional development activity was approved by Virginia Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

Protocol Support Committee
Nurse/Clinical Research Associate Continuing Education Session
PSC Discuss With Us LIVE

Date:	**Thursday, July 16, 2026**
Start and End Time:	**12:00 pm MT- 1:15 pm MT**
PSC Chair:	***Cynthia Licavoli, RN, BSN, MHA***
PSC Vice Chairs:	***Nancy Fusco, RN, BSN, CCRP & Marissa Weiss, MBA***
Format:	**Lunch & Learn Session-** ***In-person only***

PSC Discuss With US LIVE LUNCH & LEARN SESSION:
Offered In-Person only *(box lunches provided to participants who preregister by June 23, 2026)*

Learning Objectives
Following this activity, participants will be better able to:

1. Identify and discuss the patient advocate role in oncology research.

11:50 am- 12:00 pm	Pick Up Lunches & Welcome	Erin McCaig, RN, BSN
12:00 pm-1:15 pm	Patient Advocacy: Bridging the Gap between Researchers and Patients	Lisa Lenrow & Kimberly Williams

This nursing continuing professional development activity was approved by Virginia Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

Advanced Practice Providers (APP) Symposium

#NRG2026

Thursday, July 16, 2026
12:00-1:30pm MT

Program Chairs



Christa Braun-Inglis,
DNP, APRN, FNP-BC, AOCNP



Jacqueline Norrell PhD, DNP, APN, FNP-BC

Welcome & Opening Remarks



Deborah Watkins Bruner PhD, RN, FAAN
NCORP PI

Agenda

APP CTEP Policy, NCORP Guidelines
Christa Braun-Inglis

Getting Rostered, General Roles & Responsibilities as an Investigator
Mary Gulzow BS, CCRP, CORA

Update on APPs in Other Research Bases
Melyssa Foust MSN, RN, CDDR

Panel Discussion – Moderator and Introductions
Christa Braun-Inglis

1. APP Involvement in NRG Studies - NRG-CC015
   Taylor Seeley, PA
2. APP Involvement in NRG Studies - NRG-CC012CD
   Harmony Bowles PharmD, BCOP
3. APP Roles in NRG Studies - NRG-CC005
   Heather H. Albertson, RN, BSN, CCRP
4. APP Roles in NCTN/Treatment Trials
   Stephen G. Chun, MD
5. Integration of the Research APP Role into Clinical Practice Workflows
   Jacqueline Norrell

Closing Remarks
Christa Braun-Inglis & Erica Field, MPH, MHA

NRG ONCOLOGY

Session Information

Advance Practice Practitioners (APP) Symposium

Session Date: **Thursday, July 16, 2026** Session Time: **12:00 – 1:30pm (MT)**

Program Chairs: Christa-Braun-Inglis DNP APN AOCNP, Jacqueline Norrell PhD DNP APN

Learning Objectives

Following this activity, participants will be better able to:

1. Identify roles and responsibilities of the research advanced practice provider (APP) in NRG clinical trials.
2. Utilize APP CTEP Policy and NCORP guidelines in clinical practice to enhance patient safety and treatment efficacy of clinical trial participants.
3. Evaluate barriers of getting APPs rostered and integrated into NRG clinical trials, including activation.
4. Describe factors associated with successful accrual strategies and the challenges and solutions of integrating the research APP role into clinical practice workflows.

Meeting Agenda

Time	Topic	Speaker
CME		
12:00 – 12:05 PM	Welcome & Opening Remarks	Deborah Watkins Bruner PhD RN FAAN, NCORP PI Emory Nell Hodgson Woodruff School of Nursing
12:05 – 12:15 PM	APP CTEP Policy, NCORP Guidelines	Christa Braun-Inglis DNP, APN, FNP-BC, CCDR Lead, University of Hawaii Cancer Center
12:15 – 12:25 PM	Getting Rostered, General Roles and Responsibilities as an Investigator	Mary Gulzow BS, CCRP, CORA NCORP Common Spirit Health
12:25 – 12:30 PM	Update on APPs in Other Research Bases	Melyssa Foust MSN, RN, CDDR Gibbs Cancer Center & Research Institute - Spartanburg

12:30 – 1:25 PM	Panel Discussion – Moderator and Introductions	Christa Braun-Inglis DNP, APN, FNP-BC, CCDR Lead University of Hawaii Cancer Center
	1. APP Involvement in NRG Studies – NRG CC015	Taylor Seeley PA, UCHealth University of Colorado/ University of Colorado Cancer Center
	2. APP Involvement in NRG Studies – NRG CC005	Heather H. Albertson, RN, BSN, CCRP Geisinger Cancer Institute
	3. APP Involvement in NRG Studies – NRG CC012CD	Harmony Bowles PharmD, BCOP University of New Mexico Comprehensive Cancer Center
	4. APP Roles in Cancer Prevention and Control and NCTN/Treatment Trials	Stephen G. Chun MD The University of Texas MD Anderson Cancer Center
	5. Integration Research APP Role into Clinical Practice Workflows	Jacqueline Norrell PhD DNP APN FNP-BC Robert Wood Johnson Barnabas Health/Cancer Services
1:25 – 1:30 PM	Closing Remarks	Christa Braun-Inglis DNP APN FNP-BC, CCDR Lead University of Hawaii Cancer Center Erica Field MPH MHA, Director, Regulatory Administration, Publications, NCORP NRG Oncology

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

PATHOLOGY COMMITTEE

#NRG2026

Thursday, July 16, 2026
1-3 pm MT

PROGRAM CHAIRS



Jeffry Simko, MD, PhD
Chair, NRG Pathology Committee
University of California, San Francisco



Tanner Freeman, MD, PhD
Vice Chair, NRG Pathology Committee
University of Pittsburgh



Tan Ince, MD, PhD
Vice Chair, NRG Pathology Committee
Weill Cornell Medicine

PRESENTERS

Beyond the Pixel: A 30-Year Journey from Computer-Aided Diagnosis to AI-Enabled Quantitative Pathology



Metin Gurcan, PhD
Wake Forest University

NRG Biospecimen Bank Updates



Columbus
Lisa Beaverson, BA, CCRP

San Francisco
Jeffry Simko, MD, PhD





Pittsburgh
Tanner Freeman, MD, PhD

Leslie Longoria



Session Information

Pathology Committee

Session Date: **Thursday, July 16, 2026** Session Time: **1:00 – 3:00 pm MT**

Program Chairs: Jeffry Simko, MD, PhD, Chair; Tanner Freeman, MD, PhD/Tan Ince, MD, PhD, Vice Chairs

Meeting Agenda

Time	Topic	Speaker
1:00 – 1:05 pm	Welcome & Introductions	Jeffry Simko, MD, PhD (University of California, San Francisco)
1:05 – 1:35 pm	NRG Biospecimen Bank Updates:	
	Columbus	Lisa Beaverson, BA, CCRP
	San Francisco	Jeffrey Simko, MD, PhD, Leslie Longoria
	Pittsburgh	Tanner Freeman, MD, PhD
1:35 – 2:20 pm	Beyond the Pixel: A 30-Year Journey from Computer-Aided Diagnosis to AI-Enabled Quantitative Pathology	Metin Gurcan, PhD (Wake Forest University)
2:20 – 2:40 pm	Questions and Answers	
2:40 – 2:55 pm	Other Business	Jeffry Simko, MD, PhD; Tanner Freeman, MD, PhD
2:55– 3:00 pm	Closing Remarks	Jeffry Simko, MD, PhD

Protocol Support Committee

Roundtable Sessions

Nurse / Clinical Research Associate Continuing Educational Sessions

Thursday, July 16, 2026
1:30 pm - 4:45 pm MT

In-Person Only



NRG ONCOLOGY
2026 SUMMER MEETING
DENVER
#NRG2026

PROGRAM FACILITATORS

Cynthia Licavoli, RN, BSN, MHA
Marissa Weiss, MBA
Jacqueline Ludwig, RN, BSN, CCRP

TOPICS

Brain NRG Protocols

Breast (NRG-BR009) & Colorectal (NRG-GI008) Protocols

GI FORTE (NRG-CC005)

Genitourinary (GU) NRG Protocols

GYN NRG Protocols

Head & Neck NRG Protocols

Lung NRG Protocols

NRG Oncology Biospecimen Bank

NRG Oncology Quality Assurance Program

NRG Oncology Regulatory Requirements

Adverse Event Reporting

IROC Radiation Therapy/Diagnostic Imaging/TRIAD

Clinical Trials Support Unit (CTSU)

RECIST Practice

Best Practice: Informed Consent

Best Practice: Organizing Your Workday: Part 1

Best Practice: Organizing Your Workday: Part 2

Best Practice: Study Start Up, Implementation & Management

Best Practice: Site Administrator

Best Practice: Onboarding New Coordinators (Nurse/CRA)

PSC Mentorship

This nursing continuing professional development activity was approved by Virginia Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

Protocol Support Committee
Nurse/Clinical Research Associate Continuing Education Session: Roundtables

Date:	**Thursday, July 16, 2026**
Start and End Time:	**1:30 pm MT- 4:45 pm MT (In-Person Only)**
PSC Chair:	**Cynthia Licavoli RN, BSN, MHA**
PSC Vice Chairs:	**Nancy Fusco RN, BSN, CCRP & Marissa Weiss, MBA**
Program Facilitators:	**Cynthia Licavoli RN, BSN, MHA, Marissa Weiss, MBA & Jacqueline Ludwig, RN, BSN, CCRP**

Learning Objectives
Following this activity, participants will be better able to:

1. *Review and discuss key eligibility/ineligibility criteria for NRG Oncology trials.*
2. *Identify barriers for protocol enrollment to NRG Oncology trials.*
3. *Discuss key protocol logistics for NRG Oncology trials.*
4. *Identify and discuss Forte site materials for patient recruitment.*
5. *Discuss and review the basics of pathology and translational research specimen requirements and submissions.*
6. *Identify and discuss audit preparation and quality assurance management.*
7. *Discuss and review regulatory requirements.*
8. *Discuss and review adverse event reporting requirements.*
9. *Review and discuss support services available with CTSU.*
10. *Review and discuss RECIST criteria through practical application.*
11. *Review and discuss best practices for informed consents.*
12. *Identify and discuss best practice ideas for clinical trial workday organization.*
13. *Identify and discuss best practices for study startup, implementation and management.*
14. *Identify and discuss best practices for primary and affiliate site management.*
15. *Identify and discuss best practices for onboarding new coordinators.*
16. *Discuss and review the NRG Oncology Mentor Program.*

Roundtable Discussions: 20-minute rounds every 25-minutes providing 8 sessions for participants
*****Note: Refer to onsite handout, not all topics will be offered each session*****

TOPICS	**SPEAKERS**
➢ Brain NRG Protocols	Liz Wise, AAS, CCRC
➢ Breast (NRG BR009) & Colorectal (NRG GI008) Protocols	Martha Duncan, RN, MSN, Andrew Pearlman, BA
➢ GI FORTE (NRG CC005)	Cheryl Leow, MA Kristen Kotsko, RN, BSN & Lisa Barry, MEd, CCRP
➢ Genitourinary (GU) NRG Protocols	Liz Wise, AAS, CCRC
➢ GYN NRG Protocols	Izabela Frak, MA & Brianna Williams
➢ Head & Neck NRG Protocols	Jessica Leichtnam
➢ Lung NRG Protocols	Jessica Leichtnam
➢ NRG Oncology Biospecimen Bank	Lisa Beaverson BA, CCRP, Leslie Longoria, BS & Jamie Faust
➢ NRG Oncology Quality Assurance Program	Rebecca Beaulieu, MS, CCRC & Alison Ivey, DHA, MS, MBA, RN, OCN, CCRP
➢ NRG Oncology Regulatory Requirements	Judy Langer, ACRP-CP

➢ Adverse Event Reporting	Sara McCartney, MS, RN & Cortney Montgomery, RN, CCRP, CBCN
➢ IROC Radiation Therapy/Diagnostic Imaging/TRIAD	Jessica Lowenstein, MS, DABR & Denise Manfredi, BS, RT (T)
➢ Clinical Trials Support Unit (CTSU)	Rachel Albershardt, MS, CCRP
➢ RECIST Practice	Elena Nelson, MBA, CCRC
➢ Best Practice: Informed Consent	Jamie Saunders, MS
➢ Best Practice: Organizing Your Workday: Part 1	Cynthia Licavoli, RN, BSN, MHA & Erin McCaig, RN, BSN
➢ Best Practice: Organizing Your Workday: Part 2	Belinda Buehl, BS & Erin Fukaya, MS
➢ Best Practice: Study Start Up, Implementation & Management	Haley Kelly, RN, BSN & Mahjabin Noroozi, PharmD
➢ Best Practice: Site Administrator	Alex Kudryashev MS, CCRP
➢ Best practice: Onboarding New Coordinators (Nurse/CRA)	Pam Mason RN, BSN, CCRP Tiffany Elsea, BA, CCRP
➢ PSC Mentorship	Nancy Fusco, RN, BSN, CCRP

This nursing continuing professional development activity was approved by Virginia Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

Early Career & Investigator Development Committee

Investigator Development Roundtable Sessions

#NRG2026

Thursday, July 16, 2026
2:30-4:00pm MT

Session Chairs


Priya Rastogi, MD


Angeles Secord, MD


Katherine Moxley, MD

2:30-2:35 pm	Welcome & Introductions
2:35-3 pm	Session 1
3:05-3:30 pm	Session 2
3:30-3:55 pm	Session 3
3:55-4 pm	Closing Remarks

Table Topics

- Overview of NCORP Program
- NRG Breast Cancer Committee
- NRG Lung Cancer Committee
- NRG Genitourinary Cancer Committee
- NRG Gynecologic Cancer Committee
- NRG Head & Neck Cancer Committee
- NRG Trials Protocol Development
- Pathways to Successful Grants
- Trajectory for a Successful Early Career Investigator
- Health Care Access Concept Development

Attendees are invited to stay for the Investigator Networking Session immediately following, from 4-5pm MT, for an opportunity to continue conversations and build new connections.

Session Title	Early Career & Investigator Development Committee – Investigator Development Roundtable Session		
Date	July 16, 2026	**Session Chair(s)**	Priya Rastogi, MD, Angeles Alvarez Secord, MD, Katherine Moxley, MD
Time	2:30 – 4:00 pm MT	**Location**	TBD

Meeting Agenda

Time	Topic	Presenter
2:30 - 2:35pm	Welcome & Introductions	Priya Rastogi, MD
2:35 – 3:00pm	Session 1 - Attendees will pick their 1st table	
3:05 – 3:30pm	Session 2 - Attendees will pick their 2nd table	
3:30 – 3:55pm	Session 3 - Attendees will pick their 3rd table	
3:55 – 4:00pm	Room Survey/Closing Remarks	Angeles Alvarez Secord, MD

Table Topics

Table 1 – Overview of NCI Community Oncology Research Program (NCORP)	Deborah W. Bruner, RN, PhD, & Erica Field, MPH, MHA
Table 2 – NRG Disease Site Committee Activity (Breast)	Reshma Jagsi, MD
Table 3 – NRG Disease Site Committee Activity (Lung)	Kristin Higgins, MD
Table 4 – NRG Disease Site Committee Activity (GU)	Paul Nguyen, MD, Karen Hoffman, MD
Table 5 – NRG Disease Site Committee Activity (GYN)	Floor Backes, MD, Paul DiSilvestro, MD, & Roisin O'Cearbhaill, MD
Table 6 – NRG Disease Site Committee Activity (H&N)	Chris Holsinger, MD
Table 7 – NRG Trials: Protocol Development	Kathryn Okrent
Table 8 – Pathways to Successful Grants	Katherine Fuh, MD
Table 9 – Trajectory For a Successful Early Career Investigator	Jose Alejandro Rauh-Hain, MD
Table 10 – Health Care Access Concept Development	Jennifer Wenzel, MD

Additional Notes: This in-person-only session will feature three rounds of roundtable discussions, each lasting 25 minutes. Attendees are encouraged to review the list of presenters and table topics in advance and select the discussions they would like to join. Please refer to the accompanying flyer or handout for a comprehensive overview of the available topics and facilitators.

Attendees are invited to stay for the Investigator Networking Session immediately following, from 4:00–5:00 PM, for an opportunity to continue conversations and build new connections.

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

TRANSLATIONAL SCIENCE COMMITTEE

#NRG2026

Thursday, July 16, 2026
3-5pm MT

PROGRAM CHAIRS



Vered Stearns, MD
Chair, NRG Translational Science Committee
Weill Cornell Medicine



David Miyamoto, MD, PhD
Vice Chair, NRG Translational Science Committee
Mass General Brigham



Rebecca Arend, MD, MSPH
Vice Chair, NRG Translational Science Committee
University of Alabama at Birmingham

PRESENTERS



Tal Keidar Haran, MD
University of Colorado, Anschutz

Mapping the Spatial Metabolic Landscape of Radiotherapy Response



Virginia Borges, MD
University of Colorado, Anschutz

Postpartum Breast Cancer as a Translational Model for Aggressive Disease



Metin Gurcan, PhD
Wake Forest University

From Pixels to Patients: Translating Three Decades of AI in Medicine into Oncology Research and Clinical Impact

Session Information

Translational Science Committee

Session Date: **Thursday, July 16, 2026** Session Time: **3:00 – 5:00 pm MT**

Program Chair: **Vered Stearns, MD, Chair;**
David Miyamoto, MD, PhD / Rebecca Arend, MD, MSPH, Vice Chairs

Meeting Agenda

Time	Topic	Speaker
3:00 – 3:05 pm	Welcome & Introductions	Vered Stearns, MD (Weill Cornell Medicine)
3:05 – 3:30 pm	Mapping the Spatial Metabolic Landscape of Radiotherapy Response	Tal Keidar Haran, MD (University of Colorado, Anschutz)
3:30 – 3:40 pm	Questions and Answers	
3:40 – 4:05 pm	Postpartum Breast Cancer as a Translational Model for Aggressive Disease	Virginia Borges, MD (University of Colorado, Anschutz)
4:05 – 4:15 pm	Questions and Answers	
4:15 – 4:40 pm	From Pixels to Patients: Translating Three Decades of AI in Medicine into Oncology Research and Clinical Impact	Metin Gurcan, PhD (Wake Forest University)
4:40 – 4:50 pm	Questions and Answers	
4:50 – 5:00 pm	Closing Remarks	Vered Stearns, PhD

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

NCORP TOWN HALL

#NRG2026

Friday, July 17, 2026
10:00 - 11:30 am MT

PROGRAM CHAIRS



Deborah Bruner, PhD, RN, FAAN
NCORP PI
Emory University



Lisa Kachnic, MD
NCORP Co-PI
Columbia University



Julie Bauman, MD
NCORP Deputy Chair
George Washington University

CME PROGRAM



Welcome & Opening Remarks
Lisa Kachnic, MD

NRG-CC017: A Randomized Phase III Study Comparing Temporally-Modulated Pulsed Radiation Therapy (TMPRT) Versus Standard Radiation Therapy with Temozolomide for Adults with Newly Diagnosed MGMT-Unmethylated Glioblastoma



Jiayi Huang, MD
NRG-CC017 Study Chair
Washington University School of Medicine



Tony Wang, MD
NRG-CC017 NCORP Community Chair
Columbia University



Shearwood McClelland, MD
NRG-CC017 HCA Chair
University of Oklahoma Health Sciences Center

NRG-CC016: Phase III Randomized Trial: Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)



Rachel Rabinovitch, MD
NRG-CC016 Study Chair
University of Colorado Hospital

NON-CME BUSINESS



NRG NCORP Community Investigator Award
Andrew Huang, MD
Aspirus Regional Cancer Center, CROWN NCORP



NRG NCORP Next Generation Investigator award
Erin Gillespie, MD
Fred Hutchinson Cancer



NCI NCORP update
Rachel Altshuler, PhD
NCI Division of Cancer Prevention

Closing Remarks
Lisa Kachnic, MD

Session Information

NCORP Town Hall

Session Date: **Friday, July 17, 2026** Session Time: **10:00 – 11:30amMT**

Program Chairs: : Deborah Bruner, PhD, RN, FAAN; Lisa Kachnic, MD; Julie Bauman, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Objective #1 – Discuss logistics and opportunities for site participation of NRG NCORP trials.
2. Objective #2 – Evaluate strategies for enrolling participants to NRG-CC016 and NRG-CC017.

Meeting Agenda

Time	Topic	Speaker
CME		
10:00 – 10:10 AM	Welcome & Opening Remarks NRG NCORP updates	Lisa Kachnic, NCORP PI Columbia University
10:10 – 10:30 AM	NRG-CC017: A Randomized Phase III Study Comparing Temporally-Modulated Pulsed Radiation Therapy (TMPRT) Versus Standard Radiation Therapy with Temozolomide for Adults with Newly Diagnosed MGMT-Unmethylated Glioblastoma	Jiayi Huang, MD, NRG-CC017 Study Chair Washington University School of Medicine Tony Wang, MD, NRG-CC017 NCORP Community Chair Columbia University Medical Center Shearwood McClelland, MD, NRG-CC017 HCA Chair University of Oklahoma Health Sciences Center
10:30 – 10:45 AM	NRG-CC016: Phase III Randomized Trial: Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT).	Rachel Rabinovitch, MD, NRG-CC016 Study Chair University of Colorado Hospital
Non-CME Business		
10:45 – 11:00 AM	NRG NCORP Community Investigator Award	Andrew Huang, MD Aspirus Regional Cancer Center, CROWN NCORP
11:00 – 11:15 AM	NRG NCORP Next Generation Investigator award	Erin Gillespie, MD Fred Hutchinson Cancer Center
11:15 – 11:25 AM	NCI NCORP update	Rachel Altshuler, PhD NCI Division of Cancer Prevention
11:25 – 11:30 AM	Closing Remarks	Lisa Kachnic, NCORP PI Columbia University

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

GENERAL SESSION

#NRG2026

Friday, July 17, 2026
12-1 pm MT



Robert Mannel, MD Quynh-Thu Le, MD Norman Wolmark, MD

Welcome, Group Updates, & Highlights	**Robert Mannel, MD** NRG Oncology Group Chair & Program Facilitator	
NRG Research Center Update	**Mitchell Machtay, MD** NRG Oncology Deputy Group Chair	
NRG NCORP Research Base Update	**Deborah Watkins Bruner, RN, PhD** NRG NCORP PI	
NRG Statistics & Data Management Center (SDMC) Update	**James Dignam, PhD** NRG Oncology Group Statistician	
NRG Communications & Publications Update	**Harry Bear, MD, PhD** NRG Oncology Deputy Group Chair	
NRG Biospecimen Bank Update	**Jeffry Simko, MD, PhD** NRG Oncology Biospecimen Bank PI	
NRG Membership & QA Update	**David Miller, MD** NRG Oncology Deputy Group Chair	

Session Title	NRG Oncology General Session		
Date	July 17, 2026	**Chair(s)**	Robert Mannel, MD, Quynh-Thu Le, MD, Norman Wolmark, MD
Time	12:00 – 1:00pm MT	**Program Facilitator**	Robert Mannel, MD

Meeting Agenda

Time	Topic	Presenter
12:00 – 12:15pm	**Welcome, Group Updates, and Highlights**	Robert Mannel, MD, NRG Oncology Group Chair
12:15 – 12:25pm	**NRG Research Center Update**	Mitchell Machtay, MD, NRG Oncology Deputy Group Chair
12:25 – 12:30pm	**NRG NCORP Research Base Update**	Deborah Watkins Bruner, RN, PhD, NRG NCORP PI
12:30 – 12:35pm	**NRG Statistics and Data Management Center (SDMC) Update**	James Dignam, PhD, NRG Oncology Group Statistician
12:35 – 12:40pm	**NRG Communications & Publications Update**	Harry Bear, MD, PhD, NRG Oncology Deputy Group Chair
12:40 – 12:45pm	**NRG Biospecimen Bank Update**	Jeffry Simko, MD, PhD, NRG Oncology Biospecimen Bank PI
12:45 – 12:50pm	**NRG Membership & Quality Assurance Update**	David Miller, MD, NRG Oncology Deputy Group Chair
12:50 – 1:00pm	**Questions & Closing Remarks**	Robert Mannel, MD, NRG Oncology Group Chair

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

FORTE WORKSHOP: PROTOCOL COMPLIANCE BEST PRACTICES

#NRG2026

Friday, July 17, 2026
1:15-2:30pm MT



Robert Schoen, MD, MPH
University of Pittsburgh
FORTE Protocol Chair



Jeffrey Dueker, MD, MPH
University of Pittsburgh
FORTE Protocol Co-Chair

Program Facilitators: Kristen Kotsko & Cheryl Leow

AGENDA

Overview of FORTE Trial Progress	**Robert Schoen, MD, MPH**
FORTE Accomplishments: Expanding Recruitment Outreach	**Jeffrey Dueker, MD, MPH**
Innovations in Study Colonoscopy Compliance	**Jeffrey Dueker, MD, MPH**
Best Practices for Stool Collection	**Lisa Beaverson** Nationwide Childrens Hospital NRG Columbus BB
TravaLab: Implementing Mobile Phlebotomy with Remote Consent to Increase Enrollment	**Cheryl Leow, MA** FORTE Education and Communication Specialist

Session Title	FORTE Workshop: Protocol Compliance Best Practices		
Date	July 17, 2026	**Chair(s)**	Robert Schoen, MD, MPH
Time	1:15-2:30 pm	**Vice Chair(s)**	Jeffrey Dueker, MD, MPH
Program Facilitators	Kristen Kotsko, Cheryl Leow		

Meeting Agenda

Time	Topic	Presenter
1:15 pm	Welcome	
1:20 pm	Overview of FORTE Trial Progress	Robert Schoen, MD, MPH (FORTE Protocol Chair)
1:25 pm	FORTE Accomplishments: Expanding Recruitment Outreach	Jeffrey Dueker, MD, MPH (FORTE Protocol Co-Chair)
1:40 pm	Innovations in Study Colonoscopy Compliance	Jeffrey Dueker, MD, MPH (FORTE Protocol Co-Chair)
1:50 pm	Best Practices for Stool Collection	Lisa Beaverson (Nationwide Children's Hospital)
2:00 pm	TravaLab: Implementing Mobile Phlebotomy with Remote Consent to Increase Enrollment	Cheryl Leow, MA (FORTE Education and Communication Specialist)
2:10 pm	Question and Answer	ALL
2:25 pm	Call to Action	Robert Schoen, MD, MPH (FORTE Protocol Chair)

Additional Notes:

SCIENTIFIC SESSION

#NRG2026

Friday, July 17, 2026
3:00 - 4:30 PM MT

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

PROGRAM CHAIRS


Robert Mannel, MD


Angeles Alvarez Secord, MD


Mitchell Machtay, MD


Priya Rastogi, MD

Session 1: NRG Early Career Investigator Program

Moderator - Priya Rastogi, MD



Michael Toboni, MD
University of Alabama at Birmingham
NRG-GY035

Nikhil Rammohan, MD, PhD
Washington University
NRG-CC001



Session 2: NRG Oncology Recent Research Results

Moderator - Mitchell Machtay, MD



Charles Geyer, MD
University of Pittsburgh Medical Center
NSABP B-61 LidERA

Paul Harari, MD
University of Wisconsin School of Medicine and Public Health
NRG-HN009





Gregory A. Masters, MD
Helen F. Graham Cancer Center and Research Institute Christiana Care
NCTN ALCHEMIST Trial (A151216)

Amanda Nickles Fader, MD
Johns Hopkins Medicine
NRG-GY019



Session 3: Clinical Trial Accrual



James Dignam, PhD
Group Statistician, NRG Oncology
Race/Ethnicity Demographic Evaluation of NRG Oncology Clinical Trials

Thomas George, MD
University of Florida
Accelerating Trial Activation: A National Strategic Priority



Session Information

NRG Oncology Scientific Session

Date: **Friday, July 17, 2026** Time: **3:00 – 4:30pm MT**

Program Chairs: Robert Mannel, MD, Angeles Alvarez Secord, MD, Mitchell Machtay, MD, Priya Rastogi, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Evaluate emerging phase III clinical trial strategies across gynecologic, breast, lung, and head and neck cancers, including the integration of immunotherapy, targeted therapy, endocrine therapy, and optimized chemotherapy approaches.

2. Interpret recent NRG Oncology and National Clinical Trials Network (NCTN) study findings and assess their potential impact on evidence-based treatment selection and clinical practice.

3. Analyze treatment-related outcomes, including neurocognitive effects, structural brain changes, efficacy endpoints, and safety considerations, to support patient-centered decision-making.

4. Recognize opportunities to advance oncology research through clinical trial participation, accrual initiatives, and the development of innovative investigator-led studies within cooperative group settings.

Some of the presentations and discussions may include the off-label use of products/devices.

Meeting Agenda

Time	Topic	Presenter
	CME	
3:00 – 3:10 PM	Welcome & Opening Remarks	Angeles Alvarez Secord, MD Duke Cancer Institute
Session 1 – NRG Early Career Investigator Program		Moderator: Priya Rastogi, MD
3:10 – 3:20 PM	**NRG-GY035** - A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer Concept Slides: TBD	Michael D. Toboni, MD University of Alabama at Birmingham
3:20 – 3:30 PM	**NRG-CC001** - Structural Brain "Aging" and Neurocognitive Outcomes after Whole Brain Radiation Therapy: A Secondary Analysis of NRG-CC001 Concept Slides: TBD	Nikhil Rammohan, MD, PhD Washington University

Session 2 - NRG Oncology Recent Research Results		Moderator: Mitchell Machtay, MD
3:30 – 3:40 PM	**NSABP B-61 LidERA:** A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant GDC-9545 Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen-Receptor Positive, HER2 Negative Early Breast Cancer Concept Slides: TBD	Charles Geyer, MD University of Pittsburgh Medical Center
3:40 – 3:50 PM	**NRG-HN009**: Comparing Two Cisplatin Dosing Schedules Combined with Radiation for Patients with Advanced Head and Neck Cancer Concept Slides: TBD	Paul Harari, MD University of Wisconsin School of Medicine and Public Health
3:50 – 4:00 PM	**NCTN ALCHEMIST Trial (A151216):** Results of 1st generation adjuvant biologic therapy for resected lung cancer: EGFRmut cohort (erlotinib) and wild-type cohort (nivolumab) Concept Slides: TBD	Gregory A. Masters, MD Helen F. Graham Cancer Center and Research Institute, Christiana Care
4:00 – 4:10 PM	**NRG-GY019**: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Concept Slides: TBD	Amanda Nickles Fader, MD Johns Hopkins Medicine
Session 3 – Clinical Trial Accrual		
4:10 – 4:20 PM	**Race/Ethnicity Demographic Evaluation of NRG Oncology Clinical Trials**	James Dignam, PhD Group Statistician, NRG Oncology
4:20 – 4:30 PM	**Accelerating Trial Activation:** A National Strategic Priority	Thom George, MD University of Florida Health
4:30 PM	Closing Remarks	Robert Mannel, MD OU Health Stephenson Cancer Center

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

COMMUNICATIONS & DIGITAL ENGAGEMENT WORKSHOP

Virtual Session

#NRG2026

Monday, July 13, 2026
1-2pm ET / 11am-noon MT

SESSION CHAIRS



Kristin Higgins, MD
City of Hope Cancer Center



Mimi Knoll, MD
Northwell Health Cancer Institute

PRESENTERS

NRG Oncology Patient Advocate Committee Digital Visibility Campaign



Tambre Leighn
Chair, NRG Oncology Patient Advocate Committee
Healthcare Communications Consultant
Well Beyond Ordinary LLC

Lisa Lenrow
Vice Chair, NRG Oncology Patient Advocate Committee
Marketing Strategist and Patient Advocate



Tips for Engaging with Media Around Clinical Research



Suzanne Barrett
Executive Director, Marketing & Communications
City of Hope Atlanta

RECORDING AVAILABLE AFTER NRG 2026



NRG ONCOLOGY

CME / Non-CME Agendas

#NRG2026

Session Information

NRG Oncology Adaptive RT Working Group

Session Date: Thursday, July 16, 2026 Session Time: 2:00 PM – 3:00 PM Mountain Time (IN PERSON ONLY)

Program Chairs: Hyun Kim, MD, Chair Adam Yock, PhD, Vice Chair

Meeting Agenda

Time	Topic	Speaker
2:00 – 2:02 PM	Welcome & Introductions	Hyun Kim, MD
2:02 PM – 2:05 PM	Adaptive RT Trial concept update / Survey	Hyun Kim, MD, Nirav Kapadia, MD
2:05 PM – 2:10 PM	Industry Roundtable update	Hyun Kim, MD / Adam Yock, PhD
2:10 PM – 2:20 PM	Clinical Trial Pitches	
2:20 PM – 2:45 PM	Disease Site Reps and Imaging / IROC a. H&N b. CNS c. Breast d. GYN e. GI f. GU g. Lung h. Sarcoma i. Imaging Committee j. IROC k. Heme	• Nancy Lee, MD / Sharon Spencer, MD • Rupesh Kotecha, MD / Christina Tsien, MD • Hunter Boggs, MD / Rebecca Shulman, MD • Kevin Alburquerque, MD / Scott Glaser, MD • Lauren Henke, MD / Yi-Fang Wang, MD / David Horowitz, MD • Rojano Kashani, MD / Luca Valle, MD • Pamela Samson, MD / Michael Weldon, MD • Mehran Yusuf, MD / James Tsui, MD • Karthik Sundaram, MD / Dave Fuller, MD • Michael Knopp, MD/Stephen Kry, PhD • Austin Sim, MD
2:45 PM – 3:00 PM	Where do we go next?	All
	NEXT ZOOM MEETING - Zoom meetings for this WG would be 2 x's between January 2026 and July 2026. Every other month for 1 hr. **3rd Thursday** – (Held- March 19th, May 21st,) **Sept. 17th, Nov. 19th** 3:00 PM Eastern Time / 2:00 PM Central Time / 12 pm Pacific Time Hold an In Person Meeting without zoom component and No AV at NRG Oncology Meetings on Thursdays from 2 to 3 pm	

	NRG Oncology IN PERSON only meetings • **January 28**-30, 2027 – In Person Caesars Palace Las Vegas Las Vegas, NV • **July 15**-17, 2027 – In Person Marriott Marquis DC Washington, DC Adjournment	

Session Information

Brain Tumor Committee General Session

Session Date: **Friday, July 17, 2026** Session Time: **1:15pm-2:45pm MT**

Program Chair: Vinai Gondi, MD

Vice Chairs: Daniel Cahill, MD, PhD
Andrew Lassman, MD
David Raleigh MD, PhD
Erik Sulman, MD, PhD

Immediate Past Chair: Minesh Mehta, MD

Meeting Agenda

Topic	Speaker
Brain Metastasis	
NRG-BN013	Rupesh Kotecha, MD
CCTG CE.7	David Roberge, MD
NRG-CC009	Vinai Gondi, MD
NRG-BN014	Jonathan Yang, MD, PhD
Glioma	
NRG-CC017	Jiayi Huang, MD
GABLE	Christina Tsien, MD
A072301	Yoshie Umemura, MD
Meningioma	
NRG-BN003	Leland Rogers, MD
NRG-BN015	David Raleigh, MD, PhD
RTOGF 3523/Momentum-1	Sylvia Kurz, MD, PhD
NRG-BN016	John Kalapurakal, MD

Session Information

NRG Canadian Sub-committee meeting

Session Date: **Thursday, July 16, 2026** Session Time: **11:00am – 12:00pm MT**

Program Chairs: Al Covens, MD; Christina Tsien, MD

Meeting Agenda

Time	Topic	Speaker
11:00 – 11:05 AM	Welcome	Al Covens, MD
11:05 – 11:20 AM	NRG leadership update	Quynh Le, MD; Mitch Machtay, MD; Sharon Hartson, NRG Executive Director
11:20 – 11:55 AM	Updates from committee liaisons (3-5 min each)	Eva Villabla (Patient advocate) David Roberge (Brain/CNS) Katarzyna Jerzak (Breast) Sangjune Lee (GI) Eric Vigneault (GU) Lillian Gien (Gyn) Jillian Tsai (H&N) Alex Sun (Lung) Phillip Wong (Sarcoma)
11:55 AM – 12:00 PM	Closing Remarks	Christina Tsien, MD

Session Information

Session Title **Cancer Prevention and Control Committee**

Session Date: **Thursday, July 16, 2026** Session Time: **1:45pm – 3:15pm MT**

Program Chairs: Julie Bauman, MD; Tracy Crane, PhD; Stephanie Blank, MD; Mylin Torres, MD

Meeting Agenda

Time	Topic	Speaker
1:45 – 1:55 PM	Welcome CPC committee updates	Tracy Crane, PhD, Cancer Control Committee Chair
1:55 – 2:10 PM	NRG-CC2541: A Randomized Trial of Celiac Plexus SBRT Compared to Celiac Plexus Neurolysis for Pain Management in Pancreatic Cancer – The CHAPLIN trial.	Jordan Kharofa, MD, Study Co-Chair University of Cincinnati Cancer Center
2:10 – 2:25 PM	NRG Pilot Project Update, REDEL Trial: Phase II Trial of Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation	Jordan Kharofa, MD University of Cincinnati Cancer Center
2:25 – 2:40PM	NRG-CC018: MI Sleep Coach App for Cancer-Related Insomnia	Noël Arring, DNP, PhD University of Manitoba
2:40 – 3:10 PM	Panel Discussion: Clinical Trial Insights and Future Directions • NRG-CC013 • NRG-CC014 • NRG-CC015	Moderator: Julie Bauman, MD, Cancer Prevention Committee Chair Panelists: Carryn Anderson, MD University of Iowa Erin Gillespie, MD University of Washington Rocky Schoen, MD UPMC Hillman Cancer Center
3:10 – 3:15 PM	Closing Remarks	CPC Chairs

Session Information

Cervical and Vulvar Cancer Committee Meeting

Session Date: **Friday, July 17, 2026** Session Time: **8:00am MT- 10:00am MT**

Program Chairs: Charles A. Leath, III, MD, MSPH; Jyoti Mayadev, MD; Dmitriy Zamarin, MD, PhD

Learning Objectives

Following this activity, participants will be better able to:

Review recent knowledge gained in treating cervical cancer

Review open committee protocols

Reviewed current gaps in NCI cervical cancer portfolio and ways to address

Meeting Agenda

Time	Topic	Speaker
	CME	
8:00-8:15	Welcome & Opening Remarks a. Welcome, committee membership and rotation plan and review of January 2026 minutes i. Annual rotation of approximately 10% from CORE committee b. NCORP Liaison – Dr. Kathryn Mills c. Cervix updates from the Patient Advocate – Kimberly Williams	Charles A. Leath, III, MD UAB Jyoti Mayadev, MD UCSD Dmitriy Zamarin, MD, PhD, Mount Sinai NYC
8:15-8:30	AI in Medicine and Research with a focus on GYN Cancers	Yanjun Gao, PhD Univ of Colorado
8:30-8:40	Discussion and questions	Yanjun Gao, PhD Univ of Colorado
8:40-8:50	Submitted concept revision:	Sarah Lynam, MD Cleveland Med Ctr

	CV2545 Neoadjuvant cemiplimab for stage IB-II squamous cell carcinoma of the vulva: a phase II non-randomized study **CV, DT, GYN, IO**	
8:50-9:10	Concept Review and Committee Discussion	Tashana Myers, MD Emi Yoshida MD Sarah Lynam, MD Cleveland Med Ctr
9:10-9:20	Ongoing GY037 Neoadjuvant Pembrolizumab and Chemotherapy vs Chemoradiation and Pembrolizumab both followed by Pembrolizumab Maintenance for High Risk Locally **N: 336 (Phase III randomized)** **Current – 48** **Stat: Wei Deng** GY024 Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial (Brian Slomovitz / Lilian Gien) **N: 157 (Phase II)** **Current – 23** **Stat: Wei Deng**	Jyoti Mayadev, MD UCSD Dmitriy Zamarin, MD, PhD, Mount Sinai NYC Lilian Gien, MD Sunnybrook, CA
9:20-9:40	IN DEVELOPMENT UPDATES (VERBAL) **NRG GY039** A phase II non-inferiority trial of hypofractionated chemoradiation therapy versus standard chemoradiation for cervical cancer (Christina Henson) CTEP protocol development **N:550** **Stat: Wei Deng** **DT2534** Single-arm phase II alpha-particle therapy study of [203/212Pb]Pb-PDV-359 monotherapy in patients with persistent, recurrent or metastatic uterine cervix cancer that are known to be fibroblast activation protein (FAP)-positive (Denise Fabian): RS approved; to GCSC **CV2305 STRIVE** Study: **STR**atification of **V**ulvar squamous cell carcinoma by HPV and p53 status to guide **E**xcision (Jessica McAlpine/Amy Jamieson: CCTG, Ritu Salani/Lillian Gien: NRG) **N: 250 (60 from NRG) – on HOLD for submission** **Statistician: Deng Wei**	Christina Henson, MD University of OK Jyoti Mayadev, MD UCSD Lilian Gien, MD Sunnybrook, CA

	CV2538 Personalized ctDNA Response to Determine Immunotherapy Continuation in Locally Advanced Cervical Cancer (Rash, Williams, Monk, Mayadev) **DT2530** A Phase II Study of Sacituzumab Govitecan in Recurrent or metastatic Vulvar Cancer (Chambers, Backes)	
9:40-9:50	**GOG- Partners Portfolio Updates**	Leslie Randall, MD Anova Fairfax
	Operational management on-going NRG trials A. Closed Studies Protocols: 101, 120, 205, 222, 141, 173, 179, 204, 206, 240, 233, 279, 9806 B. Active / Recently Completed Trials a. **NRG-GY024** Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial (Slomovitz) N=157 i. Opened April 2021 ii. NRG Accrual 23 b. **GOG-0724/RTOG0724**: Phase III trial randomized study of concurrent chemotherapy and pelvic RT with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy. (Heidi Gray, Anuja Jhingran) i. Opened April 2009 ii. ASCO Presentation 2024 iii. Manuscript to co-authors? c. **GOG-0263**: Randomized clinical trial for adjuvant chemoradiation in post-operative cervical cancer patients with intermediate risk factors (Sang Young Ryu, Kevin A) i. Opened April 2010 ii. Amended Nov 2017 to decrease accrual from 534 to 360 iii. Closed to Accrual – 339/360 (94.2%) iv. SGO Presentation 2025 v. Published *Annals of Oncology* *vi.* QOL Manuscript *Gynecologic Oncology* d. **GOG-0278**: Evaluation of physical function and quality of life (QOL) before and after non-radical surgical therapy for stage IA1-IB1 (≤2cm) cervical cancer. (Al Covens)	

i. Opened October 1, 2012
ii. SGO Presentation 2024
iii. Published *Gynecologic Oncology*

e. **GOG-0279**: A phase II trial evaluating cisplatin and gemcitabine concurrently with intensity-modulated radiation therapy (IMRT) for the treatment of locally advanced squamous cell carcinoma of the vulva. (Neil S. Horowitz)
   i. Opened July 2, 2012
   ii. Temporarily Closed June 15,2015 after enrolling 28 in 1st stage
   iii. 2nd stage re-opened July 2016
   iv. Published *Journal of Clinical Oncology*
   To be terminated

f. **NRG-GY006**: A randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, stage II, IIIB, or IVA Cancer of the uterine cervix or Stage II-IVA vaginal cancer. (Trey Leath, Loren Mell)
   i. Opened January 15, 2016
   ii. Amendment to CTEP re: increase in accrual size and transition to Randomized phase 3
   iii. Temporarily closed secondary to drug shortage May 28, 2021
   iv. Accrual complete
   v. Published *Gynecologic Oncology*
   vi. Radiation techniques manuscript pending submission
   vii. Ongoing PET/CT analyses

g. **NRG-GY017**: Phase I trial using anti PD-L1 (atezolizumab) as immune primer and concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer. (Jyoti Mayadev)
   i. Opened October 26, 2018
   ii. Accrual: 40/40
   iii. Presentation SGO 2022 and SGO 2023; final analysis report to be performed Oct 2022
   iv. Published *Nature Communications Jan 2025*
   v. IG Brachytherapy Published *Brachytherapy 2026*
   vi. Radiation workflow In press *Int J Oncol Biol Phys*

9:50-10:00	Discussion with Committee	
	Additional Notes: Previously discussed and disapproved concepts: B. Previously Rejected Concepts a. Committee Level i. *CONTESSA (Cobb) – Fertility sparing surgery* ii. *CERVANTES (GCIG) – Follow-up to Sedlis with radical surgery and adjuvant therapy* iii. *CV1948 – Radical hysterectomy via LSC vs. Xlap (Davidson)* iv. CV2062 (Wiebe) – PROS – not approved based on design v. CV2133 (Mayadev / Mell) – Durvalumab in place of CDDP for platinum ineligible patients vi. CV2226 (Frumovitz) – PAROLA – PA lymphadenectomy study vii. KGOG 1047 (Roh) – Debulking lymphadenectomy study viii. CV2333 (Rose) – A18 Replacement ix. CV2407 (Lea/Miller) – A Phase III randomized three arm trial of concurrent chemoradiation or pembrolizumab and concurrent chemoradiation or induction chemotherapy followed by concurrent chemoradiation in locally advanced cervical cancer – Lea moved to NRG-GY037 study team PI **DT2602** A single arm, phase II open label trial of balstilimab and botensilimab for patients with persistent or recurrent cervical cancer who progressed on prior anti-PD(L)1 therapy. (Jou, Zamarin) x. b. GCSC Level i. CV1963 - Randomized Phase II Trial of Ablative Radiation Therapy for Women with Oligometastatic Recurrent Cervical Cancer (Taunk/Chino) ii. CV2220 - A Randomized Phase II Study of the Integration of Hypofractionated Image-Guided	

		Pelvic Radiotherapy Into Chemotherapy and Pembrolizumab/Bevacizumab in Newly Diagnosed Stage IVB Cervical CancerStage IVB ChemoRT (D. Chase) iii. CV2040 (Leung) – SPARTACUS II iv. PI1915 (Moxley) – PARP+ATR – Not supported by CTEP. v. PI2136 (Moxley) – PARP+ATR – Not supported by CTEP/Drug Sponsor vi. CV2432 (Washington) – T-DXd vs. TV - Accrual and Current supportive data primarily vii. CV2346 (Glaser/Yeku) – CRT with / without CPI in LN positive vulvar cancer – GCSC concern for accrual viii. DT2430 (Musa/Moore) Dual mTOR and ICB as a strategy for recurrent cervical cancer: A phase I/II study of sapanisertib plus pembrolizumab ix. **CV2540** (Pfaendler, Eskander, Santin) A Phase II open-label, randomized trial comparing the efficacy and safety of sacituzumab govitecan monotherapy vs titsotumab vedotin monotherapy in patients with recurrent, metastatic cervical cancer	

Session Information

Developmental Therapeutics Committee

Session Date: **Thursday, July 16, 2026** Session Time: **12:30 pm – 2:30 pm MT**

Program Chairs: Roisin O'Cearbhaill, MD (Dev. Therapeutics) Stephanie Gaillard, MD, PhD (Phase I)

Learning Objectives

Following this activity, participants will be better able to:

1. Participants will become familiar with the current status of translational research projects involving phase I and II studies that are under development or activated for accrual.
2. Clinical data related to novel investigational agents will be reviewed
3. Participants will learn about current CTEP assets and available supports
4. Recommendations for action by the Gyn Developmental Therapeutics Committee will be summarized

Meeting Agenda

Time	Topic	Speaker
	CME	
12:30 PM	Welcome & Opening Remarks	Drs. O'Cearbhaill, Gaillard, Corr, Backes, Alvarez
12:35 pm	Topic **Introduction**, Welcome. Review of opportunities for new investigators and discuss committee rotation. Bridges 2.0: Katherine Kurnit and Emily MacArthur New Investigator committee: Joan Tymon Rosario All core members to introduce themselves (new and old)	Drs O'Cearbhaill
12:45 pm	**Educational speaker** Bench to Bedside: Katherine Fuh (AXL story) Andres Alvarez (and how to use the translational chairs) Dmitryi Zamarin and how to use the translational chairs + Q&A	Dr Katerine Fuh, Dr Andres Alvarez and Dr Zamarin
1:30 pm	Topic **Presentation of open active studies** Concept Slides: GY022, GY031, ComboMATCH (EAY191-N4, EAY191-N5) **NRG-GY022** closure date 03/23/2026. **NRG-GY031**: N=13/60. "Amendment 4; version date: April 17, 2026 (on hold)". **EAY191-N4** accrual is open for the endometrial cohort only. **EAY191-N5:** neratinib+/- palbociclib.	Drs Sarah Taylor, Fiona Simpkins, Haider Mahdi
1:35 pm	Topic Update **DT 2534**	Dr Denise Fabian

	Concept Slides: Single-arm Phase II alpha-particle study of [$^{203/212}$Pb]Pb-PSV-359 monotherapy in patients with Persistent, recurrent or metastatic Uterine Cervix Cancer that are known to be fibroblast activation protein (FAP)-Positive. Plan for Research Strategy Committee May 2	
	Topic Updates: **DT2530:** Sacituzumab govitecan for vulva cancer Need for additional trop2 expression data in subgroups of vulva cancer (p53, HPV, other) On hold for preclinical data	Dr. Laura Chambers
	Revised CV2545 window of opportunity trial Neoadjuvant cemiplimab in vulvar cancer	Drs Sara Lynam
Non-CME Business		
1:40 – 2:20 pm	Topic New Concepts/LOI's • **DT2618** Phase 1/2 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent Endometrial Cancer (Aaron Wolfson, RadOnc) • **DT2620** Combination of pembrolizumab and Lenvatinib in patients with recurrent endometrial cancer who have progressed on first-line immunotherapy maintenance; a single arm phase II trial (Dmitrios Nasioudis)	
2:20-2:30 pm	Open discussion and closing remarks Future interim meeting: October 9, 2026 Future in person meeting: January 28-30, 2026 in Las Vegas	Drs O'Cearbhaill, Gaillard

Laura.Chambers@osumc.edu

MHARKENRIDER@lumc.edu

lrd5d@uvahealth.org

swestin@mdanderson.org

MAHDIHS@pitt.edu

Session Information

Gastrointestinal Cancer Committee Workshop

Session Date: **Saturday, July 18, 2026** Session Time: **11am – 12:30pm MST**

Program Chairs: Thomas George, MD, FACP, FASCO – CRC Chair
Scott Kopetz, MD, PhD, FASCO – CRC Vice Chair
Ted Hong, MD, FASCO – Non-CRC Chair
David Ilson, MD – Non-CRC Vice Chair

Learning Objectives

Following this activity, participants will be better able to:

Objective #1 - Appreciate the eligibility criteria and hypotheses being explored in current and upcoming NRG and select other NCTN GI Oncology clinical trials

Meeting Agenda

Time	Topic	Speaker
CME		
11:00 – 11:05 AM	Welcome & Opening Remarks	Ted Hong, MD Dana Farber/Harvard Cancer Center Thomas George, MD, FASCO Univ of Florida Health Cancer Institute
Colorectal Cancer Subcommittee – Review of NRG and Select NCTN Trials		
11:05 AM	NCTN Portfolio of NET Studies	Heloisa Soares, MD, FASCO Univ of Utah Huntsman Cancer Institute
	NRG-GI008 (CIRCULATE-NorthAmerica) ctDNA as decision tool for stage III colon cancer treatment	Arvind Dasari, MD Christopher Lieu, MD MD Anderson Cancer Center Univ of Colorado Cancer Center
	EA2222 PUMP Trial: Systemic therapy +/- HAI following 1L therapy	Motaz Qadan, MD Massachusetts General Hospital
	A022101/NRG-GI009 (ERASur) Oligo mCRC Total Ablative Therapy	Paul Romesser, MD Kate Hitchcock, MD, PhD Eric Miller, MD, PhD Memorial Sloan Kettering Cancer Center Univ of Florida Health Cancer Institute Ohio State University
	NRG-GI013 (RADIO) Ablative Liver Met Radiation for IO Response in MSS mCRC	Aparna Parikh, MD Chris Anker, MD Massachusetts General Hospital Univ of Vermont
	NEW CONCEPT - NRG-CR2524 Adaptive ctDNA-Based Treatment for mCRC	Vaia Florou, MD, MS Univ of Utah Huntsman Cancer Institute
	CCTG-032 (NEO-RT) Neoadjuvant Chemo, Excision and Observation vs. ChemoRT for Early Rectal Cancer	Noam Vanderwalde, MD, MS West Cancer Center

	NRG-CR2422 (R2B2) / JANUS (NRG-GI010)	Glen Balch, MD, MBA University of Tennessee Cancer Center
Non-Colorectal Cancer Subcommittee – Review of NRG and Select NCTN Trials		
11:45 AM	NRG GI012 Atezo/Bev +/- SBRT for HCC	Jennifer Wo, MD Massachusetts General Hospital
	NRG GI006 Phase III RCT of Protons vs. Photons for Esoph Carcinoma	Steven Lin, MD MD Anderson Cancer Center
	NRG-GI011 (LAP100) A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreatic Cancer (LAPC) Patients	Nina Sanford, MD UT Southwestern
Closing Remarks and Adjourn		

Session Information

Genitourinary Cancer Workshop Agenda

Session Date: Saturday, July 18, 2026 Session Time: 7:30 AM – 9:00 AM Mountain Time

Program Chairs: Paul Nguyen MD MBA; Rana McKay MD; Jason Efstathiou, MD DPhil; Todd Morgan, MD; Phuoc Tran MD PhD

Learning Objectives

Following this activity, participants will be better able to:

1. Recognize critical aspects of developing and conducting a clinical trial in genitourinary (GU) cancer therapy research in a cooperative group setting.
2. Identify and describe the design and status of new GU cancer clinical trials being planned and launched by NRG Oncology, to enable contribution to protocol design vetting and/or effective patient enrollment in newly-launched studies.
3. Identify and describe the status of ongoing GU cancer clinical trials being conducted by NRG Oncology, to enable effective patient enrollment in and treatment on these trials, and proper collection, submission and/or evaluation of the required patient data.
4. Identify, describe, and analyze aspects of ongoing NRG Oncology GU clinical trials which are in need of special support and improvement, to enable effective patient enrollment in and treatment on these trials, and proper collection, submission and/or evaluation of the required patient data.
5. Identify and discuss the results and publication status of GU cancer clinical trials recently completed by NRG Oncology, so they can make informed decisions based on the state of the science regarding patient treatment, and they can relay study results to patients treated on these trials.
6. Identify and describe new forms of radiotherapy delivery and their use in NRG Oncology GU cancer trials.
7. Identify and describe systemic therapies, including chemotherapeutic drugs, hormonal strategies, biologic agents, and new classes of targeted therapies that may be used in conjunction with radiation therapy in GU cancer treatment, and the effectiveness of those agents as demonstrated in NRG Oncology clinical trials.
8. Identify and describe new developments in biologic and imaging science that can be used in translational research strategies to identify GU cancer patient subgroups at risk for failure with existing treatments and identify new approaches for these patients.

Meeting Agenda

Time	Topic	Speaker
	CME	
7:30-7:35 AM	Welcome & Opening Remarks	Paul Nguyen, MD, MBA Mass General Brigham Cancer Institute
7:35 – 8:15	NRG GU008: Androgen Deprivation Therapy With or Without Radiation Therapy or Docetaxel in Patients With Node-Positive Prostate Cancer: A Phase III Randomized Trial	Ronald Chen, MD, MPH The University of Kansas
	NRG GU010 (GUIDANCE): Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-intensification and Intensification Clinical Trial (GUIDANCE)	Neil Desai, MD University of Texas Southwestern Medical Center Alejandro Berlin, MD PhD Princess Margaret Cancer Centre

	NRG-GU011: Phase II trial of PROstate oligoMETastatic radiotHErapy with or without ANdrogen deprivation therapy (NRG PROMETHEAN)	Bridget Koontz, MD AdventHealth
	NRG GU012 (SAMURAI): Phase II **S**tereotactic **A**blative Radiation Therapy (SABR) For **M**etastatic **U**nresected **R**enal Cell C**a**rcinoma (RCC) Receiving **I**mmunotherapy ("SAMURAI")	William Hall MD Medical College of Wisconsin Rana McKay MD UCSD Cancer Center
	NRG GU013 (HIGH FIVE): Five fraction radiation for high-risk prostate cancer	Karen Hoffman, MD MD Anderson Cancer Center
	NRG-GU014 PAARC: Randomized Phase II Trial Of Pembrolizumab and Radiation vs. Radiation And Concurrent Chemotherapy For High-Grade T1 Bladder Cancer	Brian Baumann, MD Springfield Clinic Scott Delacroix, MD Mary Bird Perkins Cancer Center Jason Efstathiou, MD DPhil Mass General Brigham Cancer Center
	NRG-GU015 ARCHER: The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer	Scott Delacroix, MD Mary Bird Perkins Cancer Center Himanshu Nagar, MD Memorial Sloan Kettering Cancer Center Jason Efstathiou, MD DPhil Mass General Brigham Cancer Center
	CCTG-PR26 (TRIPLE-SWITCH): Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (NCT06592924)	Edwin Posadas, MD Cedars-Sinai Medical Center
	Alliance A032302 (ASPIRE): Phase III trial of ADT + Apalutamide +/- Docetaxel in mCSPC stratified by tumor suppressor gene alterations (NCT06391340)	Paul Nguyen, MD MBA Mass General Brigham Cancer Institute
	S2427 (BRIGHT): Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT) (NCT07061964)	Sean Sachdev, MD Northwestern University
	EA8191: Phase III Study of Local or Systemic Therapy Intensification Directed in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE)	Bridget Koontz, MD AdventHealth
	S1802: Phase III Trial of Standard Systemic Therapy +/- Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer	Rich Valicenti, MD UC Davis Cancer Center
8:15– 9:00 AM	Trial Results Recap & Implications: NRG GU-005	Rodney Ellis, MD Tampa General Hospital
	NRG GU Translational Research Updates	Phuoc Tran, MD PhD MD Anderson Cancer Center
	Medical Oncology Update: ASCO 2026 updates relevant to NRG	Rana McKay, MD UCSD Cancer Center
	Urology Update	Todd Morgan, MD University of Michigan
	New Business	Group

Session Title	**NRG Oncology Health Care Access Committee(HCAC)**		
Date	7-16-2026	**Chair(s)**	Jennifer Wenzel, PhD, RN, CCM, FAAN
Time	10:15– 11:45 am MT	**Vice Chair(s)**	Evan Graboyes, MD, MPH, FACS

Meeting Agenda

Time	Topic	Presenter
10:15 - 10:25 am	Welcome /Announcements	Jennifer Wenzel, PhD, RN, CCM, FAAN
	Health Care Access Spotlights	
10:25 - 10:45 am	Bridging Research and Community: Reflections on Access, Screening, and Clinical Trial Engagement	Sherise Chantell Rogers, MD, MBA, MPH
10:45 - 11:10 am	HCAC Fellow Spotlight--Oncosexual Health and Clinical Trials	Deborah Marshall, MD, MAS
11:10 - 11:20 am	Clinical Trial Enrollment Updates - Statistics/Metrics - SDMC Reports-	Mylin Torres, MD Reena Cecchini, PhD, MS
11:20 - 11:30 am	Education and Advancement Special Interest Group Update	Victoria Bae Jump, MD, PhD Mylin Torres, MD
11:30 - 11:40 am	Rural Special Interest Group Update	Shearwood McClelland III, MD, FASCO & Parul Barry, MD, FACRO
11:40 - 11:45 am	Discussion/Wrap up	Jennifer Wenzel, PhD, RN, CCM, FAAN

Additional Notes:

HCA Special Interest Group (SIG) Breakout Sessions

The HCA Committee Meeting and HCA SIG Breakout Sessions are open to both HCA SIG members and those interested in finding out more about who we are and what we do. The SIG Breakouts will occur on ***Friday, July 17, 2026***. SIG Agendas are posted separately.

- **1:00-2:00 pm PT / HCA Concept Development Special Interest Group**
- **4:30-5:30 pm PT / HCA Older Adult Special Interest Group**

Session Information

NRG Oncology Health Care Access Committee (HCAC)

Older Adult (OA) Special Interest Group (SIG) Breakout

Session Date: **Friday, July 17, 2026** Session Time: **4:30 – 5:30 pm MT**

Program Chairs: William Tew, MD, FASCO Sindhu Kadambi, MD

Meeting Agenda

Time	Topic	Speaker
	Welcome & Introductions	William Tew, MD, FASCO Sindhu Kadambi, MD
	Enrolling/Active Protocols **HN016-**Active Protocols – Radiotherapy with Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin: A Pragmatic Phase III Randomized Trial (CONCISE) (PI: Loren Mell, MD, FASTRO) **CC017-**A randomized phase III study comparing temporally-modulated pulsed radiation therapy (TMPRT) versus standard radiation therapy with temozolomide for adults with newly diagnosed MGMT-unmethylated glioblastoma (PI: Jiayi Huang, MD)	Loren Mell, MD Sara Hardy, MD
	Defining Rural and Older Adult Measures	Shearwood McClelland III, MD, FASCO
	HCA Fellow Highlight- PROOF cohort: longitudinal changes in frailty and quality of life in ovarian and uterine cancer.	Stephaie Cham, MD
	Closing Remarks	William Tew, MD, FASCO Sindhu Kadambi, MD

Additional Notes:

HCA Special Interest Group (SIG) Breakout Sessions

The HCA Committee Meeting and HCA SIG Breakout Sessions are open to both HCA SIG members and those interested in finding out more about who we are and what we do.

Session Title	HCAC Research Concept Development Special Interest Group SIG) Breakout		
Date	July 17, 2026	**Chair(s)**	Noël Arring, DNP, PhD, RN Evan Graboyes, MD, MPH, FACS
Time	1:00 – 2:00 pm MT	**Vice Chair(s)**	

Meeting Agenda

Time	Topic	Presenter
1:00-1:05	Welcome & Introductions	Noël Arring, DNP, PhD, RN
1:05-1:15	HCA RCD Metrics Overview	Noël Arring, DNP, PhD, RN
1:15-1:55	Using Ancillary Data to Answer HCA Questions	Noël Arring, DNP, PhD, RN Reena Cecchini, PhD, MS
1:55-2:00	Closing	Noël Arring, DNP, PhD, RN

Additional Notes:

HCA Special Interest Group (SIG) Breakout Sessions

The HCA Committee Meeting and HCA SIG Breakout Sessions are open to both HCA SIG members and those interested in finding out more about who we are and what we do.

Session Information

NRG Oncology Imaging Committee
Session Date: Monday, July 13, 2026 Session Time: 1:30PM-2:30PM EST Virtual Only

Program Chairs: Karthik Sundaram MD, PhD Chair Dave Fuller MD, PhD Vice Chair

Meeting Agenda

Time	Topic	Speaker
1:30 – 1:33 PM	Welcome & Introductions	Karthik Sundaram MD, PhD Dave Fuller MD, PhD
1:33 – 1:40 PM	Update NRG Theranostics Subcommittee	Thomas Ng MD, PhD
1:40 – 1:50 PM	Disease site Updates since last meeting	
	▪ H&N	Cynthia Wu, MD
	▪ CNS	Virginia Hill, MD
	▪ Breast	
	▪ GYN	Karthik Sundaram, MD, PhD
	▪ GI	Aoife Kilcoyne, MD
	▪ GU	Bill Hall, MD
	▪ Lung	Andrew Baschnagel, MD
1:50 – 2:00 PM	Update from IROC PHL for NRG Trials	Mark Rosen, MD
2:00 – 2:15 PM	Update – Reirradiation Working Group	Martha Matuszak, PhD
2:15 – 2:30 PM	Challenges in Dose Summation	Mihaela Rosu, PhD

Session Information

NRG Immunotherapy Subcommittee

Session Date: **Tuesday, July 14, 2026** Session Time: **300-500p (ET); 100-300pm (MT)**

Program Chairs: Susanna Ulahannan, MD, Chair; Janice Lu, MD, PhD Vice Chair

Meeting Agenda

Time	Topic	Speaker
3:00 – 3:05 PM	Welcome & Introductions	Susanna Ulahannan, MD
3:05 – 4:05 PM	CIMAC-CIDC Network: Integrating translational research	Cara Haymaker, MD
	Discussion	
	Closing Remarks	Susanna Ulahannan, MD

Session Information

NRG Medical Oncology Committee

Session Date: **Monday, July 13, 2026** Session Time: **1100a-100p (ET)**

Program Chairs: Deb Armstrong, MD, Chair and Christina Wu, MD, Vice Chair

Meeting Agenda

Time	Topic	Speaker
11:00 – 11:05 AM	Welcome & Introductions	Deb Armstrong, MD
	Introduction of Vice Chair	Christina Wu, MD
11:05 – 11:10 AM	Combo Match Update	Roisin O'Cearbhail, MD
11:10 – 11:15 AM	Pharmacy Subcommittee Update	Robin Lockhorst, PharmD
11:15 – 11:20 AM	Immunotherapy Subcommittee Update	Susanna Ulahannan, MD
11:20 - 12:00 PM	Role of ctDNA Evaluation in Nonmetastatic Colon Cancer	Arvind Dasari, MD
12:00 - 12:30 PM	Non-Colorectal GI Disease Site Update	Christina Wu, MD
12:30 PM	Closing Remarks	Deb Armstrong, MD

Session Information

NRG Oncology Medical Physics Subcommittee
Session Date: Monday, July 13, 2026 Session Time: 2:30PM-4:00PM EST Virtual Only

Program Chairs: Heng Li, PhD Chair Stanley Benedict, PhD Vice Chair

Meeting Agenda

***Presented during NRG Imaging Committee Meeting / Same zoom link for both virtual meetings**

Time	Topic	Speaker
*2:00 – 2:15 PM	* Update – Reirradiation Working Group	Martha Matuszak, PhD
*2:15 – 2:30 PM	*Challenges in Dose Summation	Mihaela Rosu, PhD

Time	Topic	Speaker
2:30 – 2:32 PM	Welcome & Introductions	Heng Li, PhD Stanley Benedict, PhD
2:32 – 2:37 PM	NCI/NCTN Updates • NCI Communications • NCTN Medical Physics	Ceferino Obcemea, PhD
2:37 – 2:42 PM	Center for Innovation in Radiation Oncology (CIRO) Update	Ying Xiao, PhD
2:42 – 2:52 PM	NRG QA Report • IROC Houston • IROC Philadelphia RT (Contouring & Dosimetry)	Stephen Kry, PhD Ying Xiao, PhD
2:52 – 2:57 PM	Radiopharmaceutical Group update	Ying Xiao, PhD
2:57 – 3:22 PM	Disease site Updates since last meeting	
	▪ CNS	Yunfeng Cui, PhD / Fang-Fang Yin, PhD
	▪ Breast	Guang-Pei Chen. PhD / Jean Moran, PhD Hyejoo Kang, PhD
	▪ GI	William Parker, PhD/ Gemma Davies, PhD
	▪ GU	Mihaela Rosu, PhD/Rajat Kudchadker, PhD
	▪ GYN	Hayeon Kim, PhD / Cecilia Lee, PhD
	▪ H&N	Nataliya Kovalchuk, PhD / Ping Xia, PhD
	▪ Lung	Martha Matuszak, PhD /Timothy Ritter, PhD

	▪ Hemo	Nataliya Kovalchuk, PhD
3:22 – 3:27 PM	Modality Technology Reports • Notable Technologies (Proton) • Proton SBRT	• Liyong Lin, PhD • Liyong Lin, PhD
3:27 – 3:55 PM	Working Group and Other Updates • AI for Radiotherapy Treatment Planning • FLASH • SFRT/ Grid / Lattice • Radiomics Phantom • Data Curation	• Xun Jia, PhD / Quan Chen, PhD • Jennifer Zou, PhD • Heng Li, PhD • Jason Sohn, PhD • Yi Rong, PhD/ Quan Chen, PhD
3:55 – 4:00 PM	Other Business: Questions/ General Discussions	Heng Li, PhD Stanley Benedict, PhD

Session Information

Ovarian Cancer Subcommittee Workshop

Session Date: **Friday, July 17, 2026** Session Time: **1:00-3:00 PM Mountain Time**

Program Chairs: Chair: Kathleen Moore, MD, MS; Vice Chair: Joyce Liu, MD, MPH; Translational Chair: Rebecca Arend, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Review the status of completed and ongoing NRG/GOG clinical trials on the treatment of ovarian cancer
2. Review the status of approved NRG/GOG concepts that are under development
3. Apply standard and review procedures required to design, submit, and conduct a research protocol within NRG, including ancillary data proposals

Meeting Agenda

Time	Topic	Speaker
CME		
12:00 – 12:05 PM	Welcome & Opening Remarks	Kathleen Moore, MD, MS University of Nebraska
12:05 – 12:10 PM	Review of Closed Studies (not terminated)	Kathleen Moore, MD, MS University of Nebraska
12:10 – 12:30 PM	**Recent Trial Updates:** NRG-GY019 Concept Slides: NRG-GY019 results	Amanda Fader, MD Sidney Kimmel Cancer Center, Johns Hopkins Medicine
12:30 – 12:45 PM	**Recent Trial Updates:** NRG-GY033 Concept Slides: NRG-GY033 results	Elizabeth Hopp, MD Medical College of Wisconsin
12:30 – 12:50 PM	**Education Session:** Emerging Horizons in Immunotherapy: Bispecifics and Cellular Therapies Concept Slides: Bispecifics and Cellular Therapies	Roisin O'Cearbhaill, MD Memorial Sloan Kettering Cancer Institute
12:50 – 1:00 PM	Review of Active Studies and Approved Concepts	Kathleen Moore, MD, MS University of Nebraska
1:00 – 1:15 PM	**ComboMATCH** Update and Discussion Concept Slides: ComboMatch	Roisin O'Cearbhaill, MD Memorial Sloan Kettering Cancer Institute
Non-CME Business		
1:15 – 2:00 PM	Review of New Concepts and Concepts in Development	Kathleen Moore, MD, MS University of Nebraska Various Concept submitters and PIs

Additional Notes:

List of Closed Studies (not terminated) – status updates since Jan 2026 meeting are in blue.

Study	Title	Notes
GOG-0213	A phase III randomized controlled clinical trial of carboplatin and paclitaxel (or gemcitabine) alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian peritoneal primary and fallopian tube cancer (Robert Coleman)	Lancet Oncol 2017 NEJM 2019
GOG-0262	A randomized phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel in combination with carboplatin with or without concurrent and consolidation bevacizumab in the treatment of primary stage III or IV epithelial ovarian, peritoneal or fallopian tube cancer (John K Chan)	NEJM 2016
GOG-0273	Chemotherapy toxicity in elderly women with ovarian, primary peritoneal, or fallopian tube cancer (Vivian E von Gruenigen)	Modified dose dense cohort manuscript in draft form
GOG-0281	RP2/3 study to assess efficacy of Trametinib in recurrent or progressive low grade serous ovarian or peritoneal cancer. (David Gershenson)	Presented IGCS 2019 Lancet 2022
GOG-0264	RP2 trial paclitaxel-carboplatin vs BEP for newly diagnosed advanced-stage and recurrent chemo-naïve sex cord stromal tumors of the ovary (Jubilee Brown)	Presented IGCS 2020 Gyn Oncol 2024
NRG-GY004	Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Joyce Liu and Ursula Matulonis)	Presented ASCO 2020 J Clin Oncol 2022 OS data presented at ESMO 2023
NRG-GY005	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Jung-Min Lee and Angeles Alvarez Secord)	Closed to accrual 10/02/2020 Total accrual 562 J Clin Oncol 2024
NRG-GY009	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and Atezolizumab vs Pegylated Liposomal Doxorubicin/Bevacizumab and Atezolizumab vs Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer (Roisin O'Cearbhaill, Carol Aghajanian)	Presented IGCS 2023
NRG-GY014 (DT1718)	A Phase II study of tazemetostat (EPZ-64438), an EZH2 inhibitor, in select gynecologic cancers (NCI CRDL LOI request). Limited sample size (n = 31), but requires genomics screening. (Ramez Eskander and David Hyman)	Closed to accrual 06/15/2022 Total accrual 62 Presented SGO 2024
NRG-GY019 (RT1753)	A Phase III Randomized Three Arm trial of paclitaxel/carboplatin compared to paclitaxel/carboplatin/maintenance letrozole versus letrozole monotherapy in patients with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum. (Amanda Nickles-Fader)	Activated 8/26/19 Enrollment complete 5/12/25! Total accrual 450 Presented at SGO 2026
NRG-GY021	Randomized Phase II Trial of olaparib + tremelimumab vs olaparib in platinum sensitive recurrent ovarian cancer/HRD+ and HRD. (Sarah Adams)	Closed to accrual 10/19/2020
NRG-GY023	A randomized phase II trial of triplet therapy (a PD-L1 inhibitor durvalumab in combination with olaparib and cediranib) vs. doublet therapy (olaparib and cediranib) vs doublet therapy (durvalumab and cediranib) vs physician choice chemotherapy in women with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal or fallopian cancer who have received prior bevacizumab (Jung-min Lee)	Presented ESMO 2023 Published CCR
NRG-GY022 (DT1833)	Assessment of carboplatin clearance predictors: PK protocol to allow for extra sample collection and collection of demographic data, laboratory values, and outcome data. (Liz Villaruz/Jan Beumer)	Activated 11/2019 318/350 Now enrolling male pts only Closed to accrual 03/23/26
NRG-GY027	A Phase IB Trial of Ipatasertib plus paclitaxel and carboplatin in women undergoing neoadjuvant chemotherapy for treatment naïve, epithelial ovarian cancer (Katherine Fuh/Kathleen Moore)	Activated 6/27/2022 Enrollment complete Total accrual: 25
NRG-GY033 (RT2141)	Phase II study of androgen receptor (AR) inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent AR positive adult-type ovarian granulosa cell tumor (Elizabeth Hopp/Janet Rader)	RSC 05/2022 LOI approved 1/10/24 Activated 01/22/24 Total accrual: 17

Study	Title	Notes
		Closed for futility at interim analysis Presented at SGO 2026

List of Active Studies (all metrics are as of 06/2026) – status updates since Jan 2026 meeting are in blue.

Study	Title	Notes
NRG-CC008 (CC1923) (NC1427) (CPC1206)	A non-randomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers (SOROCk) (Walker/Huh/Pennington)	Activated 6/2020 1082/2262 **Allows surgery by non-NCTN/NCORP surgeons**
AGCT1531 (RT1205)	Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors (MaGIC, COG primary, AI Covens NRG)	Activated 5/2017 1180/2059
NRG-GY031 (DT2106)	A Phase IB study of combination BET protein inhibition (ZEN3694) and ATR kinase (M1774) for the treatment of recurrent ARID1A mutated clear cell and endometrioid ovarian carcinomas (Yasuto Kinose/Fiona Simpkins)	RSC 07/2021 LOI approved 6/21/22 Activated 08/31/23 13/57 Amendment under development
NRG-GY036 OV2307	One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum Based Chemotherapy (Ying Liu/Aghajanian)	OTF 03/17/23 RSC 05/10/23 Activated 01/16/25 269/880

List of Approved Concepts Under Development -- status updates since Jan 2026 meeting are in blue.

Concept	Title	Notes
NRG-GY038 (OV2431)	Phase II trial of sacituzumab govitecan (SG)/bevacizumab versus standard of care carboplatin, liposomal doxorubicin and bevacizumab chemotherapy in patients with platinum-sensitive ovarian cancer who have progressed on prior maintenance PARP inhibitor therapy (Porter/Santin/Liu/Moore)	OTF 11/15/24 RSC 01/22/25 GCSC 03/19/25, 06/18/25 Approval on hold 07/03/25 Full approval 08/22/25 CIRB approval pending modification 04/08/26 Protocol under dev't
OV2548	An Upfront Phase II Trial of Carboplatin/Paclitaxel +/- Pembrolizumab in Homologous Recombination Proficient Ovarian Cancer (Dinkins/Arend)	Presented 10/25
OV2615	A randomized phase II trial of pembrolizumab, oral cyclophosphamide, and bevacizumab versus standard of care oral cyclophosphamide and bevacizumab in recurrent platinum resistant ovarian cancer (Agrawal)	Presented 04/26
RT2543	Phase II Study of Sacituzumab Govitecan in Recurrent or Metastatic Low-Grade Serous Ovarian Cancer (Tymon Rosario/Santin)	Presented 10/25; IDB 02/2026; RSC 05/2026; Preparing for submission
RT2601	A study evaluating perioperative dual checkpoint blockade with chemotherapy in patients with advanced resectable clear cell ovarian cancer (Micaily, Zamarin)	Presented 01/26 and 04/26
RT2608	A randomized phase III study comparing avutometinib/defactinib/letrozole followed by letrozole maintenance versus carboplatin/paclitaxel followed by letrozole maintenance in patients with newly diagnosed advanced (stage II-IV) low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum following primary cytoreductive surgery (Cobb)	Presented 01/26; concept in development

Concept	Title	Notes
RT2616	Randomized phase II trial of ipilimumab and nivolumab versus weekly paclitaxel with bevacizumab for ovarian, fallopian tube, primary peritoneal, or endometriosis-associated clear cell carcinoma (Mathews)	Presented 04/26

Session Information

Particle Therapy Working Group

Session Date: Friday, July 18, 2025 Session Time: 10:15AM – 11:45AM Pacific Time

Program Chairs: Charles B. Simone II, MD

Meeting Agenda

Time	Topic	Speaker
10:15 – 10:17 AM	Welcome & Introductions	Charles Simone, II, MD
10:17 – 10:52 AM	Symposium: **"Understanding Fundamental Differences Between Protons and Photons to Better Inform Clinical Trial Design"** • Talk 1 – 5 minutes – How the Physical and Biological Differences Between Proton and Photon Therapy can Drive a Survival Differential *[Charles Simone, MD – NYPC/MSKCC]* • Talk 2 – 15 minutes – The potential to achieve a survival benefit without a local control improvement: lessons from the MDACC and Torpedo oropharynx randomized trials *[Anna Lee, MD – MDACC]* • Talk 3 – 10 minutes – Differential considerations for chemotherapy and immunotherapy by radiation modality *[Martin Edelman, MD – Fox Chase Cancer Center]* • 5 min open discussion	Charles Simone, II, MD (Moderator)
10:52 – 11:02 AM	Update from NCI	NCI Representative
11:02 – 11:07 AM	Update on Proton Center Credentialing by IROC	Paige Taylor, PhD
11:07 – 11:12 AM	Update on Medical Physics Proton	Liyong Lin, PhD
11:12 – 11:17 AM	GU Studies: • GU013 • GU014	Xinglei Shen, MD
11:17 – 11:22 AM	Lung Studies: • LU008 • LU011(In Development)	Charles Simone, II, MD
11:22 – 11:32 AM	H&N Studies: • HN009 • HN014 • HN015 • HN016 (In Development)	Anna Lee, MD, MPH

	• CC013	
11:32 – 11:37 AM	GI Studies • GI006 • GI003 closed • GI012 • GI013 (In Development) • GI015 (In Development)	Steven Lin, MD, PhD GI006 Ted Hong, MD
11:37 – 11:42 AM	CNS Studies: • BN003 • BN014 • BN015 (in Development)	Rupesh Kotecha, MD
11:42 – 11:45 AM	Open Discussion	All

Session Information

Patient-Centered Outcomes Research (PCOR) Committee Agenda

Session Date: **Thursday, July 16, 2026** Session Time: 3:30-5:00 pm Mountain Time

Program Chairs: Ron Chen, MD and Samantha Tam, MD

Meeting Agenda

Time	Topic	Speaker
3:30 – 3:35 PM	Welcome & Introduction	Ron Chen, MD
3:35 – 3:45 PM	Introduction of Dr. Tam– New PCOR Vice-chair	Samantha Tam, MD
3:45 – 4:05 PM	**VOICE-AE**: Voice-based Oncology Intelligent Clinical Evaluation of Adverse Events	Mark Waddle, MD
4:05 – 4:15 PM	PRO and QOL Data Compliance Update	Marcie Ritter, PhD Kandie Dempsey, DBA, MS, RN, OCN
4:15 – 4:25 PM	Role of PCOR Liaisons	Ron Chen, MD
4:25 – 4:45 PM	Liaison Updates and Developing Concepts • BN2526 • LU012	Ron Chen, MD Samantha Tam, MD
4:45 – 4:50 PM	Closing Remarks	Ron Chen, MD Samantha Tam, MD

Session Information

NRG Radiation Oncology Committee

Session Date: **Friday, July 17, 2026**

Session Time: **8:00AM – 10AM Mountain Time**

Program Chairs: Evan Wuthrick, MD Chair

Charles B. Simone II, MD and Diandra Ayala-Peacock, MD Vice Chairs

Meeting Agenda

Time	Topic	Speaker
8:00 – 8:05 AM	Welcome & Introductions	Evan Wuthrick, MD
8:05 – 8:10 AM	NCI/NCTN Updates • NCI Communications • NCTN Medical Physics CIRO Updates	NCI Representative Ying Xiao, PhD
8:10 – 8:15 AM	NRG Imaging Committee	Dave Fuller, MD, PhD
8:15 – 8:45 AM	GYN RO Working Group Adaptive RT Working Group Theranostics Subcommittee	Matthew Harkenrider, MD Hyun Kim, MD Jeff Michalski, MD
8:45 – 8:55 AM	NRG RO Particle Therapy Working Group	Charles Simone II, MD
8:55 – 9:05 AM	NRG RO Medical Physics Subcommittee	Heng Li, PhD
9:05 – 9:20 AM	Imaging and Radiation Oncology Core Group • IROC Philadelphia • IROC Contouring and Dosimetry • IROC Houston	Ying Xiao, PhD Denise Manfredi, BS Paige Taylor, PhD
9:20 – 9:55 AM	Disease Site Reports – Updates on concepts near development a. H&N - Jimmy Caudell, MD /Jason Chan, MD b. CNS- Christina Tsien, MD / Tony Wang, MD c. Breast -Steven Chmura, MD/Jose Bazan. MD d. GYN- Eric Donnelly, MD / Mark Bernard, MD e. GI – William Hall, MD / Kimberly Mak, MD f. GU - James Randall, MD / Xinglei Shen, MD g. Lung - Stephen Chun MD /Pamela Samson, MD h. Sarcoma - Philip Wong, MD / Dian Wang, MD	H&N: Jason Chan, MD CNS: Christina Tsien, MD Breast: Jose Bazan, MD GYN: Mark Bernard, MD GI: Kimberly Mak, MD GU: Xinglei Shen, MD Lung: Stephen Chun, MD Sarcoma: Dian Wang, MD
9:55 – 10:00 AM	Questions.	All

Session Information

NRG Oncology Radiation Oncology GYN Working Group
Session Date: Thursday, July 16, 2026 Session Time: 4:30PM-5:30PM PST – IN PERSON

Program Chairs: Matthew Harkenrider, MD, Chair Diandra Ayala-Peacock, MD, Vice Chair

Meeting Agenda

Time	Topic	Speaker
4:30 – 4:35 PM	Welcome & Introductions/ Announcements	Matthew Harkenrider, MD, Diandra Ayala-Peacock, MD
4:35 – 4:40 PM	Future Meeting Schedule • Virtual Interim Meeting Fall 2026, concepts due 4-5 weeks in advance • Zoom Meeting Prior to NRG Meetings for new GYN RT Concepts (1-2 weeks prior) • **January 28**-30, 2027 Caesars Palace Las Vegas Las Vegas, NV	Matthew Harkenrider, MD Diandra Ayala-Peacock, MD
4:40 – 5:05 PM	**Educational Session: Molecular Classification of Uterine Cancer: Ancillary Analyses of GOG 249 and GOG 258**	Aine Clements, MD Lindsay Kuroki, MD, MSCI
5:05 – 5:10 PM	Discussion of New Concepts	
5:10– 5:25 PM	Discussion of Previously Approved Concepts	
5:25 – 5:30 PM	Old Business/New Business Concluding Remarks and Wrap-Up QUESTIONS / DISCUSSION	Matthew Harkenrider, MD, Diandra Ayala-Peacock, MD

Session Information

Rare Tumour

Session Date: **Thursday, July 16, 2026** Session Time: **1430-1630**

Program Chairs: Allen Covens,MD ; Jubilee Brown, MD

Learning Objectives

Following this activity, participants will be better able to:

Discuss past, ongoing, and emerging NRG clinical trials in rare gynecologic cancers

Discuss priorities and promising preclinical and translational objectives for future clinical trials

Discuss outcome from preclinical workshop and strategies to increase the portfolio of clinical trials in rare gynecologic cancers

Discuss potential collaborative Research Initiatives

Note

This meeting will include off-label use of various therapies/devices

Meeting Agenda

Time	Topic	Speaker
	CME	
1430 – 1435	Welcome & Opening Remarks	Allen Covens,MD Jubilee Brown, MD
	Active Studies **AGCT1531:** A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors COG lead group. Stratum 2 is Temporarily Closed, Accrued 1183/1780	Allen Covens,MD
	AGCT1532: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors. COG lead group. Accrued 204/250	Allen Covens,MD
	A091903: A Randomized Phase II Trial Of Adjuvant Nivolumab With Or Without Cabozantinib In Patients With Mucosal Melanoma. Registration to Arm 3 is Temporarily Closed to Accrual 103/99 patients	Danielle Vicus, MD
	Previously Approved studies **RT2543** Phase II Study of Sacituzumab Govitecan in Recurrent or Metastatic Low-Grade Serous Ovarian	Joan Rosario, MD

	Cancer (Rosario) NCI call 1/26- approved by RSC in May. LOI to NCI	
	RT2536 An International Phase III Trial of the efficacy of adjuvant chemotherapy compared to hormonal therapy/surveillance in adult patients with advanced/metastatic or recurrent granulosa cell tumor (GHOST trial) (Gien, Ray-Coquard) on hold pending European funding- letter of support sent	Lilian Gien, MD
	In Development **RT2601** A phase II, frontline study evaluating perioperative dual checkpoint blockade with chemotherapy in patients with advanced, resectable clear cell ovarian cancer. Revised, and phase I thru DT cmte	Ida Macailey, MD
	RTM2616 Randomized phase II trial of ipilimumab and nivolumab versus weekly paclitaxel with bevacizumab for ovarian, fallopian tube, primary peritoneal, or endometriosis-associated clear cell carcinoma. Tabled previously Resubmitted concept	Cara Matthews, MD Reviewers: Ken Lin, MD
	RT2608 A randomized phase III study comparing avutometinib/defactinib/letrozole followed by letrozole maintenance versus carboplatin/paclitaxel followed by letrozole maintenance in patients with newly diagnosed advanced (stage II-IV) low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum following primary cytoreductive surgery. Awaiting NRG confirmation of holding IND, and stats	Lauren Cobb, MD
	Working Groups **LGSO**	Mark Carey, MD Amanda Nickels Fader, MD
	Clear Cell Ovary	John Farley MD Elisabeth Stover MD
	Stromal Tumours	Elizabeth Hopp MD Tyler Hillman, MD
	Other Business	

Session Information

NRG Oncology Theranostics Subcommittee
Session Date: Thursday, July 16, 2026 Session Time: 3:00PM-4:00PM Mountain Time – IN PERSON

Program Chairs: Jeff Michalski, MD, Chair Thomas Ng, MD, PhD and Oliver Sartor, MD, Vice Chairs

Meeting Agenda

Time	Topic	Speaker
3:00 – 3:05 PM	Welcome & Introductions	Jeff Michalski, MD Thomas Ng, MD Oliver Sartor MD
3:05 – 3:55 PM	Institutional technology survey/assessment located on NRG Website Radiopharmaceutical Therapy - NRG Oncology Theranostics Subcommittee - NRG Oncology	Thomas Ng MD, PhD
	Industry relationships / Industry Roundtable meeting	Jeff Michalski, MD Thomas Ng, MD Oliver Sartor MD
	Concept generation/ Protocol Development a. Data gathering of potential study topics	All
	NCI Update	NCI Representative
	Theranostics Dosimetry / Physics QA	Ying Xiao, PhD
	Imaging – NM/DR / IROC	Karthik Sundaram, MD/ Dave Fuller, MD / Michael Knopp, MD, PhD
	Medical Oncology	Oliver Sartor, MD
	Disease site Updates since last meeting	
	▪ GU	Angela Jia, MD/ John Floberg, MD
	▪ GI	Kathryn Hitchcock, MD/ Hyun Kim, MD
	▪ Brain	Erik Sulman, MD/ Daniel Cahill, MD
	▪ Lung	Marty Edelman, MD/ Salma Jabbour, MD
	▪ H & N	Heath Skinner, MD /Hyu Kang, MD
	▪ Breast	Steve Chmura, MD
	▪ GYN	Jyoti Mayadev, MD/ Paul DiSilvestro, MD
3:55- 4:00PM	**Open discussion / New Business** • Future Meeting Schedule - Hold 2 Zoom meetings between Winter and Summer NRG Oncology meetings.	All

	• *2026 – Zoom meetings: ~~April 9th~~ (held May 21st) and October 8th -2nd Thursday* • *2027 – Zoom meetings: April 8th and October 14th -2nd Thursday* NRG Oncology IN PERSON only meetings • **January 28**-30, 2027 – In Person • Caesars Palace Las Vegas • Las Vegas, NV • **July 15**-17, 2027 – In Person • Marriott Marquis DC • Washington, DC	

Session Information

Translational Science Brain Tumor Working Group

Session Date: **Friday, July 17, 2026** Session Time: **10:50 – 11:50 am MT**

Program Chairs: Erik Sulman, MD, PhD and David Raleigh, MD, PhD, Chairs

Meeting Agenda

Time	Topic	Speaker
10:50 – 10:55 am	Welcome & Introductions	Erik Sulman, MD, PhD (Duke University) and David Raleigh, MD, PhD (University of California, San Francisco)
10:55 – 11:05 am	Evaluation of tumor associated P30-peptide antigen (ETAPA) in glioblastoma	Kelly Hotchkiss, PhD (Duke University)
11:05 – 11:10 am	Questions and Answers	
11:10 – 11:20 am	Chemoradiotherapy response after vorasidenib in IDH-mutant glioma mouse model	Diana Shi, MD (Massachusetts General Brigham)
11:20 – 11:25 am	Questions and Answers	
11:25 – 11:35 am	Radiopharmaceutical therapy for leptomeningeal metastases	Mahua Dey, MD (University of Wisconsin-Madison)
11:35 – 11:40 am	Questions and Answers	
11:40 – 11:50 am	Closing Remarks	Erik Sulman, MD, PhD and David Raleigh, MD, PhD

Session Information

Translational Science Genitourinary Cancer Working Group

Session Date: **Friday, July 17, 2026** Session Time: **4:30 – 6:00 pm MT**

Program Chair: **Phuoc Tran MD, PhD, Chair**

Meeting Agenda

Time	Topic	Speaker
4:30 - 4:35 pm	Welcome & Introductions	Phuoc Tran, MD, PhD (MD Anderson Cancer Center)
4:35 – 5:00 pm	Mapping the Spatial Metabolic Landscape of Radiotherapy Response	Tal Keidar Haran, MD (University of Colorado, Anschutz)
5:00 – 5:25 pm	Enabling Biomarker-Driven GU Cancer Trials: Genomic Capabilities and Collaborative Opportunities	Holli Dilks, PhD (Foundation Medicine)
5:25 – 5:50 pm	Circulating Biomarkers in Oligometastatic GU Cancers	Chad Tang, MD (MD Anderson Cancer Center)
5:50 – 6:00 pm	General Translational Science Project Updates & Closing Remarks	Phuoc Tran, MD, PhD

Session Information

Translational Science Gynecologic Cancer Working Group

Session Date: **Friday, July 17, 2026** Session Time: **4:30-6:00pm**

Program Chairs: Michael J Birrer, MD, PhD, and Heather A Lankes, PhD, MPH

Meeting Agenda

Time	Topic	Speaker
4:30 – 4:35 PM	Welcome & Introductions	Michael J Birrer, MD, PhD Heather A Lankes, PhD, MPH
4:35 – 4:50 PM	Genomic and molecular characterization of biomarkers associated with self-reported race/ethnicity in high-risk endometrial cancers from NRG Oncology/GOG Protocol 210, Molecular Staging of Endometrial Cancer	Casey Cosgrove, MD
4:50 – 5:05 PM	Uterine Corpus Subcommittee	Vickie Bae-Jump, MD, PhD Katherine Fuh, MD, PhD
5:05 – 5:20 PM	Cervix/Vulva Subcommittee	Dmitriy Zamarin, MD, PhD
5:20 – 5:35 PM	Ovarian Subcommittee	Rebecca Arend, MD
5:35 – 5:50PM	Developmental Therapeutics	Andres Alvarez-Pinzon, MD, PhD, EMHA
5:50 - 6:00 PM	Closing remarks	Michael Birrer, MD, PhD Heather Lankes, PhD, MPH

Session Information

Translational Science Head and Neck Cancer Working Group

Session Date: **Friday, July 17, 2026** Session Time: **1:00 pm – 3:00 pm MT**

Program Chairs: **Neil Hayes, MD, PhD, Chair; Sidharth Puram, MD, PhD, Vice Chair**

Meeting Agenda

Time	Topic	Speaker
1:00 – 1:05 pm	Welcome & Introductions	Neil Hayes, MD, MS, MPH (University of Tennessee Health Science Center)
1:05 – 1:30 pm	Personalizing Radiotherapy for Head and Neck Cancer	James Caudell, MD, PhD (Moffitt Cancer Center)
1:30 – 1:40 pm	Questions and Answers	
1:40 – 2:05 pm	Reimagining EGFR Targeting in HNSCC: Beyond Cetuximab and Revisiting an Abandoned Target	Trisha Wise-Draper, MD, PhD (University of Cincinnati Cancer Center)
2:05 – 2:15 pm	Questions and Answers	
2:15 – 2:55 pm	Translational Science Head and Neck Cancer Working Group meeting	Neil Hayes, MD, PhD; Sidharth Puram, MD, PhD
2:55 – 3:00 pm	Closing Remarks	Neil Hayes, MD, MS, MPH

Additional Notes:

Session Information

Translational Science Lung Cancer Working Group

Session Date: **Friday, July 10, 2026** Session Time: **1:00 – 3:30 pm ET**

Program Chair: Puneeth Iyengar, MD, PhD

Meeting Agenda

Time	Topic	Speaker
1:00 – 1:05 pm	Welcome & NRG Lung Trial Updates	Puneeth Iyengar, MD, PhD (Memorial Sloan Kettering Cancer Center)
1:05 – 1:25 pm	Pipeline/Product Updates and Opportunities for Collaboration	Kathryn Gillis, PharmD; Kang Lu, PhD (Regeneron)
1:25 – 1:30 pm	Questions and Answers	
1:30 – 1:50 pm	Pipeline/Product Updates and Opportunities for Collaboration	Nabil Chehab, MD (AstraZeneca)
1:50 – 1:55 pm	Questions and Answers	
1:55 – 2:15 pm	Pipeline/Product Updates and Opportunities for Collaboration	Sherif El-Refai, PharmD, PhD (Personalis)
2:15 – 2:20 pm	Questions and Answers	
2:20 – 2:40 pm	Pipeline/Product Updates and Opportunities for Collaboration	Jason Porter, MD; Michael Krawczyk (Guardant)
2:40 – 2:45 pm	Questions and Answers	
2:45 – 3:05 pm	Pipeline/Product Updates and Opportunities for Collaboration	Quentin Chometon; Noah Waterfield Price, PhD (Optellum)
3:05 – 3:25 pm	Questions and Answers	
3:25 – 3:30 pm	Closing Remarks	Puneeth Iyengar, MD, PhD

Session Information

Uterine Corpus Cancer Subcommittee

Session Date: **Friday, July 17, 2026** Session Time: **10:00am-12:00pm MT**

Program Chairs: Matthew Powell, MD; Ann Klopp, MD

Vice Chairs: Katherine Fuh, MD, PhD; Victoria Bae-Jump MD, PhD

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss national and international priorities, goals and initiatives in the management of Uterine cancer.
2. Discuss currently active and developing NRG clinical trials on the prevention, diagnosis, and treatment of uterine corpus cancers.
3. Discuss promising therapeutics in development and potential translational research objectives and strategies for future clinical trials.
4. Apply standards and procedures needed to design, submit, (revise), and conduct a research protocol within the NRG
5. Outline both potential barriers and potential solutions to improve enrollment to NRG clinical trials in uterine corpus cancers to include international collaboration

**NOTE IF YOUR NAME IS HIGHLIGHTED, PLEASE PREPARE A REVIEW OF THE CONCEPT. IF YOUR NAME IS LISTED FIRST YOU SHOULD BE THE PRIMARY REVIEWER AND COORDINATE COMMENTS FROM THE OTHER REVIEWERS.

Meeting Agenda

Time	Topic	Speaker
	CME	
10:00 – 10:10 AM	Welcome, Introductions	Matthew Powell, MD Ann Klopp, MD
10:10-10:30	Endometrial Cancer Molecularly Targeted Therapy Consortium	Dr. Angeles Alvarez Secord
10:30-11:15	New Concept Review: Primary review: 1. UC2619 Investigation of Sacituzumab Govitecan in patients with chemo-resistant Gestational Trophoblastic Neoplasia; a single arm phase II trial. Reviews with other committees being primary: 2. DT2618 Phase 1/2 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent Endometrial Cancer	1. Dimitrios Nasioudis MD PI,Lainie Martin MD CO-PI Discussants: Helen Mackay, Marilyn Huang, Sarah H. Kim 2. Discussants: Jessica St. Laurent, Floor Backes, Therese Youssef Andraos

	3. RT2616 Randomized phase II trial of ipilimumab and nivolumab versus weekly paclitaxel and bevacizumab (and pembrolizumab in PD-L1+) ovarian, fallopian tube, primary peritoneal, or endometriosis-associated clear cell carcinoma	3. Discussants: Allison Puechl, Dana Chase, Marina Frimer
11:15-11:45	Review of open and recently closed trials Concept Slides: *Powell slides*	Helen MacKay, MD Ramez Eskander, MD Floor Backes, MD Matthew Powell, MD Britt Erickson, MD Lindsey Kuroki, MD Casey Cosgrove, MD
1145-11:55	Review of studies in development Concept Slides: *Klopp slides*	Ann Klopp, MD
11:55-12:00 PM	Closing Comments	Matthew Powell, MD



NRG ONCOLOGY

Institutional Accrual

#NRG2026

Accrual For Agenda Book from 1/1/2026 to 6/30/2026 Run Date: 7/9/2026				
NRG Main Member (Network)	CTEP ID	Accrued to NRG Studies	Accrued to Non-	Total
AdventHealth Orlando	FL086	2	0	2
Allan Blair Cancer Centre	11076	2	0	2
Allegheny General Hospital	PA009	4	2	6
Arizona Center for Cancer Care-Peoria	AZ127	0	1	1
Arthur J E Child Comprehensive Cancer Centre	11134	2	0	2
Ascension Alexian Brothers - Elk Grove Village	IL280	0	0	0
Aurora NCI Community Oncology Research	AURORA	10	32	42
Avera Cancer Institute	SD021	4	3	7
Baptist Health Cancer Research Network	BHCRN	10	18	28
Baptist MD Anderson Cancer Center	FL003	0	5	5
Bay Pines VA Healthcare System	FL051	34	0	34
Baylor College of Medicine/Dan L Duncan	TX041	0	0	0
Baystate Medical Center	MA004	5	1	6
BCCA-Vancouver Cancer Centre	11081	9	0	9
Boston Medical Center	MA043	3	0	3
Cancer Research Consortium of West Michigan	CRCWM	13	1	14
Cancer Research for the Ozarks NCORP	OZARKS	30	1	31
Cancer Research of Wisconsin and Northern	CROWN	33	2	35
Cancer Trials Ireland	ICORG	10	0	10
Carle Cancer Center NCI Community Oncology	CARLE	24	0	24
Carolinas Medical Center/Levine Cancer	NC042	15	2	17
Cedars-Sinai Medical Center	CA016	14	16	30
Centre Hospitalier Universitaire de Sherbrooke-	11065	5	0	5
Chinese University of Hong Kong-Prince of	34003	0	0	0
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)	11073	28	0	28
CHUM - Centre Hospitalier de l'Universite de	11062	6	0	6
City of Hope Comprehensive Cancer Center	CA043	5	8	13
CIUSSSEMTL-Hopital Maisonneuve-Rosemont	11060	3	0	3
Columbia University NCI Community Oncology	COLUMBIA	7	1	8
Columbus NCI Community Oncology Research	COLUMBUS	6	0	6
CommonSpirit Health Research Institute	CORA	14	1	15
Cooper Hospital University Medical Center	NJ036	19	9	28
Corewell Health William Beaumont University	MI005	3	2	5
Covenant Health Cancer Centers	TN038	1	0	1
Covenant Medical Center-Lakeside	TX054	0	0	0
Cross Cancer Institute	11132	0	0	0
CWRU Case Comprehensive Cancer Center	LAPS-OH029	46	1	47
Dana-Farber / Partners CancerCare LAPS	LAPS-MA036	8	0	8
Danbury Hospital	CT030	2	6	8
Dartmouth College - Dartmouth Cancer Center	LAPS-NH012	7	0	7
Dayton NCI Community Oncology Research	DAYTON	1	0	1
Delaware/Christiana Care NCI Community	CHRISTIANA	10	0	10
Dell Seton Medical Center at The University of	TX063	0	1	1
Duke University - Duke Cancer Institute LAPS	LAPS-NC010	16	1	17

Edward Hospital/Cancer Center	IL104	7	4	11
Emory University - Winship Cancer Institute	LAPS-GA005	31	3	34
Essentia Health NCI Community Oncology	ESSENTIA	4	0	4
Fox Chase Cancer Center	PA086	11	0	11
Fred Hutchinson Cancer Research Center LAPS	LAPS-WA008	14	2	16
Froedtert and the Medical College of Wisconsin	LAPS-WI013	33	1	34
Gastro Health Support Center	GHSC	15	0	15
Geisinger Cancer Institute NCI Community	GEISINGER	17	0	17
George Washington University Medical Center	DC014	1	1	2
Georgia CaRes	GACARES	12	0	12
Georgia NCI Community Oncology Research	GEORGIA	1	11	12
Global Oncology Trials Japan	GOTJ	29	0	29
Greater Baltimore Medical Center	MD018	3	4	7
Gulf South Clinical Trials Network (Gulf South	GULFSOUTH	41	0	41
Hackensack University Medical Center	NJ022	3	1	4
Hartford Hospital	CT009	4	4	8
Heartland Cancer Research NCORP	HEARTLAND	17	1	18
Henry Ford Hospital	MI026	17	0	17
Houston Methodist Hospital	TX036	6	1	7
Indiana University - Melvin and Bren Simon	LAPS-IN007	18	3	21
Intermountain Medical Center	UT056	1	0	1
Iowa-Wide Oncology Research Coalition	IWORC	19	15	34
Jewish General Hospital	11116	2	0	2
JHU Sidney Kimmel Comprehensive Cancer	LAPS-MD017	10	2	12
Juravinski Cancer Centre at Hamilton Health	11183	2	0	2
Kaiser Permanente NCI Community Oncology	KAISER	499	46	545
Kaiser Permanente-Gaithersburg Medical	MD198	12	0	12
Kantonsspital Aarau	67029	6	0	6
Lahey Clinic	MA017	2	0	2
Lankenau Medical Center	PA125	1	0	1
Laura and Isaac Perlmutter Cancer Center at	NY011	33	0	33
Legacy Good Samaritan Hospital and Medical	OR013	6	0	6
Loyola University Medical Center	IL017	4	0	4
MaineHealth Cancer Care Network	MAINE	8	0	8
Mayo Clinic LAPS	LAPS-MN026	54	13	67
Medical University of South Carolina NCORP	MUSC	28	0	28
MedStar Franklin Square Medical	MD029	4	0	4
Memorial Sloan-Kettering Cancer Center LAPS	LAPS-NY016	36	2	38
Metro Minnesota Community Oncology	METROMIN	54	1	55
Miami Cancer Institute	FL078	7	15	22
Miami Valley Hospital	OH084	2	6	8
Michigan Cancer Research Consortium NCORP	MCRC	34	0	34
Michigan Healthcare Professionals Farmington	MI310	0	0	0
Michigan State University	MI038	0	0	0
Moffitt Cancer Center	FL065	22	1	23
Montana Cancer Consortium NCORP	MONTANA	5	1	6
Montefiore Academic Community NCORP	MONTEFIORE	10	3	13

Mount Sinai Hospital	NY021	11	5	16
MU Health - University Hospital/Ellis Fischel	MO036	6	0	6
National Cancer Centre Singapore	47005	2	0	2
National Institutes of Health Clinical Center	MD004	0	5	5
NCORP of the Carolinas (Prisma Health NCORP)	GREENVILLE	33	1	34
Nebraska Methodist Hospital	NE007	4	2	6
Nevada Cancer Research Foundation NCORP	NCRF	1	0	1
New York-Presbyterian/Brooklyn Methodist	NY075	26	2	28
NorthShore University HealthSystem-Evanston	IL018	4	0	4
Northwell Health NCORP	NORTHWELL	15	3	18
Northwestern University LAPS	LAPS-IL036	19	7	26
Norton Hospital Pavilion and Medical Campus	KY049	5	0	5
Odette Cancer Centre- Sunnybrook Health	11118	29	0	29
Ohio State University Comprehensive Cancer	LAPS-OH007	58	10	68
Oklahoma Cancer Specialists and Research	OK037	9	3	12
Oregon Health and Science University	OR010	5	0	5
Orlando Health Cancer Institute	FL020	11	4	15
Ottawa Hospital and Cancer Center-General	11025	3	0	3
Pacific Cancer Research Consortium NCORP	PCRC	29	0	29
Parkview Regional Medical Center	IN181	1	0	1
Penn State Milton S Hershey Medical Center	PA042	12	4	16
Peter MacCallum Cancer Centre	3003	3	0	3
Piedmont Hospital	GA027	3	0	3
ProMedica Flower Hospital	OH012	1	1	2
Puerto Rico NCI Community Oncology Research	PUERTORICO	35	0	35
Reading Hospital	PA107	1	10	11
Regents of the University of Michigan	LAPS-MI014	7	0	7
Rhode Island Hospital	RI005	1	2	3
Riverside Methodist Hospital	OH008	14	0	14
Roswell Park Cancer Institute	NY158	2	0	2
Rush MD Anderson Cancer Center	IL043	1	2	3
Rutgers Cancer Institute of New Jersey LAPS	LAPS-NJ066	27	1	28
Saint Joseph Hospital - Orange	CA087	0	1	1
Saint Joseph's Hospital and Medical Center	AZ009	0	0	0
Sanford NCI Community Oncology Research	SANFORD	36	3	39
Sarah Cannon Cancer Center	TN047	5	1	6
Saskatoon Cancer Centre	11120	2	0	2
Seoul National University Hospital	43002	18	0	18
Southeast Clinical Oncology Research	SCOR	30	1	31
Stanford Cancer Institute Palo Alto	CA141	13	0	13
State University of New York Upstate Medical	NY141	8	1	9
Stony Brook University Medical Center	NY184	4	11	15
Stroger Hospital of Cook County (SHCC) NCORP	STROGER	9	0	9
Summa Health System - Akron Campus	OH055	0	1	1
Sutter Cancer Research Consortium	SUTTER	16	23	39
The Hawaii NCORP	HAWAII	18	4	22
The James Graham Brown Cancer Center at	KY002	3	19	22

The NCI Community Oncology Research	NEWMEXICO	43	3	46
The Research Institute of the McGill University	11318	9	0	9
The University of Kansas Cancer Centers- MCA	KANSAS	40	2	42
Thomas Jefferson University Hospital LAPS	LAPS-PA121	18	16	34
Tibor Rubin VA Medical Center	CA041	0	0	0
Trinity Cancer Care Center	ND026	0	0	0
TROG Cancer Research	TROG	11	0	11
Tulane University School of Medicine	LA001	0	1	1
UC Irvine Health/Chao Family Comprehensive	CA088	15	0	15
UC San Diego Moores Cancer Center	CA249	17	0	17
UCLA / Jonsson Comprehensive Cancer Center	CA006	8	3	11
UCSF Medical Center-Mount Zion	CA136	13	1	14
UF Health Cancer Institute - Gainesville	FL015	15	22	37
UNC Lineberger Comprehensive Cancer Center	NC007	9	0	9
University Health Network-Princess Margaret	11030	11	0	11
University of Alabama at Birmingham / Deep	LAPS-AL002	9	0	9
University of Arizona LAPS	LAPS-AZ017	9	0	9
University of Arkansas for Medical Sciences	AR006	11	0	11
University of California Davis Comprehensive	CA189	9	3	12
University of Chicago Comprehensive Cancer	LAPS-IL057	17	8	25
University of Cincinnati Cancer Center-UC	OH070	8	1	9
University of Colorado Cancer Center LAPS	LAPS-CO070	36	0	36
University of Illinois	IL040	6	4	10
University of Iowa/Holden Comprehensive	IA018	19	0	19
University of Kentucky/Markey Cancer Center	KY010	1	0	1
University of Maryland/Greenebaum Cancer	MD015	40	7	47
University of Miami Miller School of Medicine-	FL028	44	3	47
University of Minnesota/Masonic Cancer	MN022	5	0	5
University of Mississippi Medical Center	MS005	0	0	0
University of Nebraska Medical Center	NE003	10	3	13
University of Oklahoma Health Sciences Center	LAPS-OK003	29	1	30
University of Pennsylvania LAPS	LAPS-PA075	6	0	6
University of Rochester LAPS	LAPS-NY167	17	0	17
University of South Alabama Mitchell Cancer	AL068	0	0	0
University of Tennessee - Knoxville	TN021	1	5	6
University of Tennessee Health Science Center	TN030	0	0	0
University of Texas Health Science Center at	TX059	5	0	5
University of Texas MD Anderson Cancer	LAPS-TX035	35	1	36
University of Texas Medical Branch	TX045	0	0	0
University of Texas Southwestern Medical	LAPS-TX011	17	0	17
University of Utah - Huntsman Cancer Institute	LAPS-UT003	6	0	6
University of Vermont and State Agricultural	VT004	32	4	36
University of Wisconsin Carbone Cancer Center	LAPS-WI020	24	5	29
UPMC Hillman Cancer Center LAPS	LAPS-PA015	52	6	58
Upstate Carolina Consortium Community	UPSTATE	23	0	23
USC Norris Comprehensive Cancer Center LAPS	LAPS-CA011	7	0	7
UVA Comprehensive Cancer Center	VA009	18	2	20

Vanderbilt University - Ingram Cancer Center	LAPS-TN008	5	0	5
VCU Massey Comprehensive Cancer Center NCI Community Oncology Research Program	VCU	13	12	25
Wake Forest University Health Sciences	NC002	8	0	8
Walter Reed National Military Medical Center	MD001	0	0	0
Washington University - Siteman Cancer Center	LAPS-MO011	33	4	37
Wayne State University/Karmanos Cancer	MI020	1	0	1
WellSpan Health-York Hospital	PA047	10	6	16
West Virginia University Charleston Division	WV004	0	1	1
West Virginia University Healthcare	WV025	24	23	47
Western States Cancer Research NCORP	WESTERN	0	0	0
Wisconsin NCI Community Oncology Research	WINCORP	10	1	11
Women and Infants Hospital	RI012	15	7	22
Women's Cancer Center of Nevada	NV049	23	0	23
Yale University - Yale Cancer Center LAPS	LAPS-CT018	27	0	27
Yonsei University Health System-Severance	43027	2	0	2

NRG2026Travel Awardees

Congratulations to all of the members who received travel awards to the NRG 2026 Summer Meeting. We look forward to your involvement and contributions!

Rebecca Baca

Edward Bleta

Cynthia Dwight

Brandi Jansen

Nedra Johnson

Dana Kontras

Brittany Lansford

Katie Lee


Samantha Pifer

Joshua Schiff

Joan Tymon-Rosario

Yingzhi Wu

Jessica Ziegelbein



Sponsors & Exhibitors

Platinum Swag Sponsor

AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives. Our commitment is measured by the impact we make – to patients, to our communities, and to the world. Our approximately 50,000 employees strive to make a remarkable impact that lasts, driven by our compassion for people, commitment to innovation and inclusion, service to the community and uncompromising integrity. Today our products help more than 60 million people living in more than 175 countries, and we are making significant advancements with a robust pipeline of potential new medicines as we look to find the treatments of tomorrow.

Platinum Swag Sponsor

Corcept Therapeutics

Corcept Therapeutics is a commercial-stage pharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more than 25 years, Corcept's singular focus on cortisol modulation has led to the discovery of more than 1,000 proprietary selective cortisol modulators that have the potential to deliver improved patient outcomes across a wide range of diseases. In February 2012, the company introduced Korlym® (mifepristone), the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing's syndrome. Corcept is headquartered in Menlo Park, California. For more information, visit Corcept.com.

Aadi Bioscience

At Aadi Bioscience, our mission is to improve the lives of people with mTOR-driven diseases. We believe success depends on addressing the limitations of current mTOR inhibitors and leveraging the latest genomic profiling technology to identify the patients most likely to benefit from mTOR inhibition. We currently have FYARRO® which is approved in the United States for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

AstraZeneca

We are a global, science-led, patient-focused pharmaceutical business. We are committed to excellence in the research, development and commercialisation of prescription medicines. We aim to transform the lives of patients with improved outcomes and a better quality of life.

Caris Life Sciences

Caris Life Sciences is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. With a primary focus on cancer, Caris suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. To learn more, please visit www.CarisLifeSciences.com.

Sponsors & Exhibitors

Eisai
As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.

Genmab
Genmab's purpose is to improve the lives of patients through innovative and differentiated antibody therapeutics. Pioneering technologies that create novel antibody therapeutics to treat cancer and other serious diseases.

GSK
GSK Oncology's mission and purpose is to deliver potentially transformative medicines and industry-leading programs that provide enduring impact and hope for our patients and their loved ones.

IROC
The Imaging and Radiation Oncology Core (IROC) provides integrated radiation oncology and diagnostic imaging quality control programs in support of clinical trials conducted by NRG Oncology and the other Network Groups in the National Clinical Trials Network. IROC staff are here to answer study data submission related radiation therapy and diagnostic imaging questions from investigators or other clinical research professionals.

Merck
At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

Natera
Signatera is a custom-built circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) assessment and treatment response monitoring in patients previously diagnosed with cancer. Signatera’s performance has been clinically validated in multiple solid tumors including colorectal, breast, and bladder cancers as well as for immunotherapy response monitoring.

Sponsors & Exhibitors

Veracyte
Veracyte offers the Decipher Prostate Genomic Classifier to help with treatment planning for prostate cancer. Decipher Prostate provides prognostic information to help assess each patient's individual risk and has been validated in over 95 studies as the most accurate predictor of metastasis, prostate cancer-specific mortality, and overall survival.

Verastem
Verastem Oncology is late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

Exhibit Hall Schedule:
Thursday 7:00am – 6:00pm
Friday 7:00am – 5:30pm
Saturday 7:00am – 12:30pm

Complimentary coffee, tea, and soft drinks will be served in the exhibit area at specified times on each day that exhibits are open.

I AM TAMI.

Known for my curiosity. Not my cancer.



We are AbbVie.
Pursuing innovation in cancer treatment for people like Tami.

Tami,
Real patient with ovarian cancer

abbvie

People. Passion. Possibilities.®

Visit abbvie.com to learn more.

Lifyorli™

(relacorilant) 100 mg, 25 mg capsules

Now Approved[1]

Scan the QR code, or visit
LIFYORLIhcp.com for more information!

Reference: 1. LIFYORLI. Prescribing Information. Corcept Therapeutics Incorporated.

LIFYORLI and the LIFYORLI logo are trademarks of Corcept. Corcept and the Corcept logo are registered trademarks.
© 2026 Corcept. US-LIF-26-0025 04-26

GILEAD
Oncology

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Update

The NCCN Guidelines® for Breast Cancer have been updated to Version 3.2026

The recommendation for recurrent unresectable or stage IV disease for hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (triple-negative breast cancer; TNBC) has been updated.

- **Sacituzumab govitecan-hziy is recommended as an NCCN Category 1, preferred option for 1L metastatic TNBC PD-L1 CPS <10 and no germline *BRCA1/2* PV**
- **Sacituzumab govitecan-hziy + pembrolizumab is recommended as an NCCN Category 1, preferred option for 1L metastatic TNBC for patients with PD-L1 CPS ≥10 regardless of germline *BRCA1/2* PV status**

Sacituzumab govitecan-hziy also remains an NCCN Category 1, preferred option in 2L metastatic TNBC.

The use of sacituzumab govitecan-hziy ± pembrolizumab in patients with previously untreated, locally advanced unresectable or metastatic triple-negative breast cancer is investigational. Sacituzumab govitecan-hziy is not approved for this use and the efficacy and safety for this use have not been established.

Table 1. NCCN Guidelines recommended cytotoxic regimens for recurrent unresectable (local or regional) or stage IV (M1) disease[a]

HR-negative and HER2-negative (TNBC)		
Setting	**Subtype/biomarker**	**Regimen**
First line	PD-L1 CPS ≥10[b] regardless of germline *BRCA1/2* PV status[c]	Chemotherapy (albumin-bound paclitaxel, carboplatin/gemcitabine, or paclitaxel) + pembrolizumab[d] (Category 1, preferred)
		Sacituzumab govitecan-hziy[e] + pembrolizumab[d] (Category 1, preferred)
	PD-L1 CPS <10[b] and no germline *BRCA1/2* PV[c]	Sacituzumab govitecan-hziy (Category 1, preferred)[e,f]
		Datopotamab deruxtecan-dlnk (Category 1, preferred)
		Systemic chemotherapy
	PD-L1 CPS <10[b] and germline *BRCA1/2* PV[c]	PARPi (olaparib or talazoparib) (Category 1, preferred)
		Platinum (carboplatin or cisplatin) (Category 1, preferred)
Second line	Germline *BRCA1/2* PV[c]	PARPi (Category 1, preferred)
	Any	Sacituzumab govitecan-hziy[e,f] (Category 1, preferred)
		Systemic chemotherapy or targeted agents
	No germline *BRCA1/2* PV[c] and HER2 (*ERBB2*) IHC 1+ or 2+/ISH negative[g]	Fam-trastuzumab deruxtecan-nxki[h] (other recommended)
Third line and beyond	Biomarker positive (ie, MSI-H, *NTRK1/2/3* and *RET* gene fusions, TMB-H)	Targeted agents and emerging biomarker options
	Any	Systemic chemotherapy

Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V3.2026. © 2026 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. **To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.** The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.

Note: All recommendations are category 2A unless otherwise indicated. Category 2A indicates that based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
Category 1 indicates that based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.

The National Comprehensive Cancer Network® (NCCN®) recommendations differ from the sacituzumab govitecan-hziy (TRODELVY®) Prescribing Information.

[a]For treatment of brain metastases, see NCCN Guidelines for Central Nervous System Cancers.
[b]Programmed death ligand 1 (PD-L1) expression is assessed using 22C3 antibody. Threshold for positivity combined positive score (CPS) ≥10.
[c]Assess for germline *BRCA1/2* PVs in all patients with recurrent or metastatic breast cancer to identify candidates for PARPi therapy.
[d]While available data are in the first-line setting, this regimen can be used for second and subsequent lines of therapy if programmed cell death protein 1 (PD-1)/PD-L1 inhibitor therapy has not been previously used. If there is disease progression while on a PD-1/PD-L1 inhibitor, there are no data to support an additional line of therapy with another PD-1/PD-L1 inhibitor.
[e]See NCCN Guidelines for Hematopoietic Growth Factors.
[f]Sacituzumab govitecan-hziy may be considered for second or later line if not used in a previous line of therapy.
[g]See NCCN Guidelines for Breast Cancer: Principles of HER2 Testing (BINV-A). The distinction between HER2 (*ERBB2*) test results of IHC 0/absent membrane staining, IHC 0+/with membrane staining (faint, partial membrane staining in ≤10%), IHC 1+, or 2+/ISH negative is currently clinically relevant for therapy selection.
[h]Fam-trastuzumab deruxtecan-nxki may be considered in a later line for HER2 (*ERBB2*) IHC 1+ or 2+/ISH negative, if not used in second line or may be considered first-line therapy when disease has progressed during or within 6 months after completing adjuvant chemotherapy. Fam-trastuzumab deruxtecan-nxki is associated with interstitial lung disease (ILD)/pneumonitis. Regular monitoring for this serious side effect is recommended. For patients with a history of ILD/pneumonitis, there are no data on managing safety or toxicity of this drug in a trial.

1L, first line; 2L, second line; *BRCA*, breast cancer gene; *BRCA1/2*, breast cancer gene 1/2; CPS, combined positive score; *ERBB2*, erb-b2 receptor tyrosine kinase 2 gene; FDA, US Food and Drug Administration; HER2, human epidermal growth factor receptor 2; HER2–, human epidermal growth factor receptor 2–negative; HR–, hormone receptor–negative; IHC, immunohistochemistry; ILD, interstitial lung disease; ISH, in situ hybridization; MSI-H, microsatellite instability-high; mTNBC, metastatic triple-negative breast cancer; NCCN, National Comprehensive Cancer Network; *NTRK1/2/3*, neutrophic tyrosine receptor kinase genes; PARP, poly (ADP-ribose) polymerase; PARPi, poly (ADP-ribose) polymerase inhibitors; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; PV, pathogenic variant; *RET*, rearranged during transfection gene; TMB-H, tumor mutational burden-high.

APPROVED INDICATIONS

Sacituzumab govitecan-hziy (TRODELVY®) is indicated for the treatment of adult patients with

- Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease
- Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting

IMPORTANT SAFETY INFORMATION

BOXED WARNING: NEUTROPENIA AND DIARRHEA

TRODELVY® can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY® for absolute neutrophil count below 1500/mm^3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay.

TRODELVY® can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY® until resolved to ≤ Grade 1 and reduce subsequent doses.

CONTRAINDICATIONS

Severe hypersensitivity reaction to TRODELVY®.

WARNINGS AND PRECAUTIONS

- Hypersensitivity and Infusion-Related Reactions: Hypersensitivity reactions including severe anaphylactic reactions have been observed. Monitor patients for infusion-related reactions. Permanently discontinue TRODELVY® if severe or life-threatening reactions occur.
- Nausea/Vomiting: Use antiemetic preventive treatment and withhold TRODELVY® for patients with Grade 3 nausea or Grade 3-4 vomiting at the time of scheduled treatment.
- Patients with Reduced UGT1A1 Activity: Individuals who are homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia following initiation of TRODELVY® treatment.
- Embryo-Fetal Toxicity: TRODELVY® can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 25%) (including laboratory abnormalities) were decreased leukocyte count, decreased neutrophil count, decreased hemoglobin, diarrhea, nausea, decreased lymphocyte count, fatigue, alopecia, constipation, increased glucose, decreased albumin, vomiting, decreased appetite, decreased creatinine clearance, increased alkaline phosphatase, decreased magnesium, decreased potassium, and decreased sodium.

Please see the full Prescribing Information for additional safety information.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V3.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed May 11, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org.

GILEAD | Oncology

If you wish to contact Gilead Medical Affairs, click here.

TRODELVY®, GILEAD, and the GILEAD Logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
333 Lakeside Drive, Foster City, CA 94404.

© 2026 Gilead Sciences, Inc. All rights reserved. MA-TRO-NA-US-00075 MRC Approved 27 MAY 2026

Thank You

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

NRG ONCOLOGY
SUPPORTERS PROGRAM PARTNERS

NRG Oncology would like to thank our Supporter Program partners for their contributions to NRG Oncology and their commitment to helping us advance our mission to improve the lives of those impacted by cancer.

ASSOCIATE SPONSOR:

GILEAD SCIENCES, INC.

ALLY SPONSORS:

NATERA **NOVARTIS** **VERACYTE**

Thank You

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

NRG Oncology would like to thank and acknowledge the following companies for providing Independent Medical Education (IME) grant support associated with the 2026 Summer NRG Oncology Semiannual Meeting.

COOPER SURGICAL

EISAI

EXACT SCIENCES/ABBOTT

GSK

MERCK

SIEMENS/VARIAN MEDICAL SYSTEMS

Thank You

NRG ONCOLOGY
2026 SUMMER MEETING
DENVER

NRG Oncology Foundation and The GOG Foundation would like to thank and acknowledge the following companies for providing Independent Medical Education (IME) grant support associated with the 2026 Summer NRG/GOG Joint Educational Symposium entitled:

“Ovarian Cancer Prevention is Our Duty-When We Fail: Recurrence Mitigation and Treatment Strategies for Ovarian Cancer”

ABBVIE

ASTRAZENECA

CORCEPT

ELI LILLY

GSK

VERASTEM

LABCORP

NRG ONCOLOGY


Future Meeting Dates & Locations



January 28-30, 2027 - Las Vegas, NV



July 15-17, 2027 - Washington, DC



January 19-21, 2028 - San Francisco, CA